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ABSTRACT
In this dissertation, ultrasonication assisted Layer-by-Layer (LbL) technology for the 
preparation o f multifunctional poorly water-soluble anticancer drug nanoparticles, paclitaxel 
and lapatinib, has been developed. Many FDA approved drugs are very low soluble in water; 
therefore, it is very difficult to load and control their release and targeting efficiently, which 
greatly confines their application. The development o f this method will pave the way for the 
development and application o f those low soluble anticancer drugs.
In the first part o f this dissertation, the first approach for powerful ultrasonication, the 
top-down approach (sonicating bulk drug crystals in polyelectrolyte solution), was 
successfully applied for the preparation o f the nanoparticles o f paclitaxel. For this approach, 
a 200 nm diameter was a kind o f “magic” barrier for colloidal particles prepared. This 
diameter barrier may be related to the nucleation size o f the solvent vapor microbubbles. 
Consequently, agents enhancing bubbling formation (such as NH 4 HCO 3 ) were applied to 
decrease paclitaxel colloid particles to 100-120 nm. Those paclitaxel nanoparticles were 
Layer-by-Layer coated with a 10-20 nm polycation/polyanion shell to provide aqueous 
colloidal stability and slower particle dissolution. However, a large obstacle o f these 
powerful ultrasonication methods was a necessity o f long ca 45 minutes high power 
ultrasonication which resulted in TiCL contamination from titanium electrode. The small 
amount o f TiCL contamination from ultrasonication did negatively affect the in vivo testing o f
this system in mice, and had to be removed before low toxicity o f the Layer-by-Layer coated 
pacclitaxel nanoparticles were observed.
In the second part o f the dissertation, the second approach for sonication, the bottom-up 
approach (sonicating drug in a water-miscible organic solvent followed by slow water 
add-in) was successfully applied for the preparation o f the nanoparticles o f lapatinib and 
paclitaxel with less powerful sonication. By using polymeric excipients combined with 
non-ionic and anionic surfactants along with regular sonication, the prepared particle sizes 
was uniform at around 140-150 nm. Less sonication time (ca 15 minutes) and lower 
sonication power avoided TiCL contamination. The amphiphiles attached to the hydrophobic 
nanoparticles and served as anchors for LbL shell. The inner LbL layers and surfactants 
minimized the surface free energy, thereby preventing crystal form changes and nanoparticles 
coalescence, while the outermost layers enhanced colloidal stability.
In the third part o f the dissertation, LbL shells with PEGylation (using a block 
copolymer o f poly-L-lysine (PLL) and PEG) for lapatinib were developed for enhanced 
colloidal stability in high molarity PBS buffer.
In the above proposed paclitaxel and lapatinib formulation, we obtained 150-200 nm 
with high drug content o f 80-90% due to very thin capsule walls (ca 10 nm). The drug release 
time from the LbL capsules was found to be between 10 and 20 hours depending on the shell 
thickness. Washless Layer-by-Layer assembly was used: 1) addition o f polycation in the 
amount that is enough to reverse surface charge of the dispersion to a high positive (+30 mV) 
value; 2 ) addition of polyanion in the amount that is enough to reverse surface charge o f the 
dispersion to a high negative (-30 mV) value. No intermediate washing o f nanoparticles was 
done until the shell was complete. The washless method had the advantage o f time and 
energy saving, preservation o f the sample structure and no losses o f sample.
In the last part o f the dissertation, we elaborated nanoformulation o f two drugs in one 
nanocapsule locating paclitaxel in the core and lapatinib on the shell periphery. With this 
formulation, combining in one nanoparticle dual drugs, we reached the drugs' efficiency 
synergy. In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, LbL 
lapatinib/paclitaxel nanocolloids mediated an enhanced cell growth inhibition in comparison 
with the LbL paclitaxel-only and LbL lapatinib-only treatment, not to say the free one drug 
treatment.
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CHAPTER 1
INTRODUCTION
In this chapter, the motivation and background for the dissertation is described. The 
technology gaps for the existing drug delivery system, an introduction for sonication assisted 
Layer-by-Layer technology and how it may help in solving existing problems are described. 
The outline o f the dissertation is also shown. Some sections o f  this chapter were published in 
a paper written by the author o f this dissertation in co-authorship with Dr. Lvov and our 
Italian collaborators as “Drug-loaded polyelectrolyte microcapsules for sustained targeting of 
cancer cells,” in Advanced Drug Delivery Reviews, v 63, 847-864, 2011. The text sections 
cited from this paper is properly cited (see Ref. 27), and they are not in use in any other 
dissertation.
1.1 Motivation and Background
1.1.1 Statement o f Problem and Significance
Cancer remains one o f the most challenging diseases. In America, 11.4 million people 
alive have a cancer history. More than 1500 people die o f cancer every day, accounting for 
one fourth o f total deaths. More than 1,500,000 new cancer cases are diagnosed yearly. The 
NIH (National Institute o f Health) estimated the costs o f cancer for 2010 to be over 260 
billion dollars. Among the costs, the direct medical costs were over 100 billion dollars; the 
indirect loss of productivity by illness costs was over 2 0  billion dollars; the indirect mortality 
cost was over 140 billion dollars [1-2].
Traditional cancer treatments often have side effects o f killing healthy cells and causing 
toxicity to patients. Therefore, it is o f great importance to develop new therapeutics which 
can effectively target cancerous cells [3]. The needed features o f pharmaceutical drug 
delivery (small size, biodegradability, high content o f  a drug in preparation, prolonged 
circulation in the blood, and the ability to target required organs) are reasonably well met by 
liposomes, microcapsules, and nanoparticles for well water-soluble drugs. The development 
o f  nanoparticle drugs having all o f  these properties for low soluble pharmaceuticals represent 
a challenge.
Drug delivery systems (DDS) are designed to enhance the pharmacokinetics and 
therapeutic performance o f  drugs [4], In fact, they may pave the way for achieving Nobel 
Prize winner Paul Erich’s “magic bullet.” One o f the intensely studied DDS is the magnetic 
field manipulated drug delivery systems, because magnetic materials are biodegradable and 
can be given endovascular and act at a relatively long range [5]. This system also can be 
helpful for imaging [5]. However, the drug loading capacity o f these systems is relatively low 
for cancer treatment, and this is even more conspicuous for the many poorly soluble drugs.
Many efficient cancer drugs (for example, paclitaxel, lapatinib, atovaquone, curcumin, 
camptothecin, and tamoxifenetc) approved by FDA are poorly soluble in water. However, 
their bioavailability is low for treatment, and many of them are not only toxic to cancer cell 
but also toxic to normal cells. Paclitaxel is a representative poorly soluble drug which could 
be used to treat various cancers such as lung, ovarian, and breastcancers [6 ]. However, it is 
very difficult to load and control its release target and rate efficiently by conventional 
technique [7-10], Therefore, the application scope o f poorly soluble drugs has been confined 
[11-12],
Layer-by-Layer (LbL) self-assembly has been a well-established method for 
nanofabrication and nanoarchitechure build-up. LbL's versatility can be very useful for
3building up the drug delivery system. We used Layer-by-Layer coating technology to 
establish a simple, effective method for preparing multifunctional poorly soluble drug 
nanoparticles which can become stable, targeted releasable, traceable, aqueous and bioactive 
nanoparticles with high concentration (more than 50%) o f the active drug. Due to these 
multifunctional properties, the poorly soluble drug nanoparticles could be used for achieving 
our object o f early detection, diagnostics, and prognostics for cancer diseases. Here, we used 
paclitaxel and lapatinib as representative poorly soluble anticancer drugs and aimed at 
establishing simple, effective methods in cancer research and nanomedicine and to develop 
chemotherapeutics that can target cancerous cells. Our research was superior to micelle 
carriers and other techniques in universality o f method (for micelle carrier technology, 
different drug requires different condition to become soluble), multifunction (targeting, 
imaging, proper usage o f anti-angiogenesis agents), drug concentration (more than 50% 
compared with less than 5%), stability (high and low), and controllability o f  release rate (easy 
and difficult). O f course, in this work, we accomplished these goals only partially.
To sum up, our approach may be helpful for establishing simple in preparation stable 
nanocolloids o f low soluble drugs which otherwise do not have means for delivery. For this 
research, we solved the following tasks: 1) forming o f 200-300 nm nanocores o f paclitaxel 
and lapatinib through ultrasonication and modified solvation methods; 2 ) making stable nano 
colloids o f these drugs in water, 3) making this nanocolloids stable at 0.1 M NaCl solution 
and PBS buffer at concentration o f 1-2 mg/ml through architectural design o f LbL shells with 
PEGylation; 4) optimizing drug release rate through adjustment of the polyelectrolyte layer 
number in the capsule shell, and 5) combining these two drugs (paclitaxel and lapatinib) in 
one nanocapsules for enhanced anticancer efficiency. The nanocapsule targeting, though, 
which may be performed with this method o f architectural shell through including 
immunoglobulins in the outermost shell, is out o f the scope o f this work.
41.1.2 Drug Delivery Systems (DDSt
Drug delivery systems are the development of tailored systems which help deliver a 
certain amount o f one (or more) therapeutic drug(s) to a targeting point, at a certain 
controlled release rate, with or without the existence o f  a specific trigger [13],
The US demand for drug delivery systems (including the value o f the delivered drugs) 
will increase over ten percentannually to $132 billion in 2012 [14], which will well justify 
this work. In a further introductory section, we will use sections o f our review paper in 
Advanced Drug Delivery Reviews, 2011, p. 847-864 with appropriate reference V. Vergaro, F. 
Scarlino, C. Bellomo, M. Maffia, X. Zhang, Y. Lvov, S. Leporatti, “Drug-loaded 
polyelectrolyte microcapsules for sustained targeting of cancer cells” Advanced Drug  
Delivery Reviews, v 63, 847-864, 2011.
Oral drug delivery systems will continue to account for the largest share (50%) o f 
demand through 2 0 1 2  due to favorable cost advantages, a wealth of potential new product 
applications and significant efficacy advantages over conventional dosage formulations. 
Parenteral preparations will provide the strongest growth opportunities for drug delivery 
systems, with demand expanding over 15% annually through 2012 (32% share). While the 
Inhalation & Other account for 18% o f the total share. An increasing incidence o f chronic 
respiratory conditions will keep demand for inhalation drug delivery systems advancing 
favorably [14].
Medicines adapted to a controlled-release matrix, diffusion and reservoir systems will 
post favorable sales gains as drug makers seek to gain competitive advantages by introducing 
new, improved formulations o f off-patent pharmaceuticals. Improved solubility and 
pharmacokineticactions will lead to rapid growth both in the number and sales o f drug 
nanoparticles [14],
5Primary goals for drug delivery systems include (i) target drug delivery, (ii) drug toxicity 
reduction while maintaining therapeutic effects, (iii) greater safety and biocompatibility and 
(iv) faster and lasting development o f medicines. To reach these purposes, a deep 
investigation about drug incorporation and release, in order to maximize drug loaded into 
nanocarriers, as well as biocompatibility and bio-distribution information are also essential 
[13, 15].
The major drug delivery systems developed are micellar nanocarriers, magnetic field 
manipulated DDS, liposomes, dendrimers, solid lipid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC), fullerenes and nanotubes (CNT & Halloysite) etc. They 
are briefly discussed below.
1.1.2.1 Magnetic Field Manipulated DDS
One of the intensely studied DDS is the magnetic field manipulated drug delivery system. 
Since magnetic materials are biodegradable and can be given endovascular and act at 
relatively long range [5]. Furthermore, this system can be helpful for imaging [5], Most 
common magnetic nanoparticles are iron peroxide (Fe3 0 4 ) NPs o f 15-60 nm diameters [16]. 
They generally are made by a magnetic core and then coated with natural or synthetic 
polymers. Natural compounds widely used are carbohydrates, such as dextran, and proteins 
that are usually cross-linked to avoid their degradation in aqueous solutions. Synthetic 
coating materials are PEG, PLA and PVA, which have a higher mechanical strength than 
other natural chemicals [17].
Other metallic nanoparticles used are gold shell nanoparticles, which have a dielectric 
core covered by a thin metallic gold shell. Their properties make them useful mostly for 
biomedical imaging and therapeutic applications [16]. Recently, Lee et al. developed 
magnetism-engineered iron oxide (MEIO) nanoparticles for the detection o f target biological 
molecules in vivo [18]. When conjugated with an antibody, MnMEIO-Herceptin conjugates
6demonstrated enhanced sensitivity for cancer cell detection as well as for in vivo imaging o f 
small tumors.
However, the drug loading capacity o f these systems is relatively low for cancer 
treatment and this capacity is even more conspicuous for the many poorly soluble drugs. 
Besides, it is unclear how to remove inorganic components from the patient organism.
1.1.2.2 Liposomes and Micelles
Micelles are nanoscopic self-assembling core-shell structural colloidal particles, one o f 
the most commonly studied drug delivery system, and in some cases, micelles can serve as 
drug delivery systems for poorly soluble pharmaceuticals. Their hydrophobic cores can be 
used for encapsulation o f  many poorly soluble drugs with increased stability and good 
biocompatibility [7-10].
However, micelles are far from satisfactory because o f their low loading efficacy, 
problems with controlling the release rate o f the drug and other problems.
Liposomes are small vesicles composed by amphiphilic phospholipids enclosing an 
interior aqueous space, within the range o f 50 to 1000 nm [19], Phospholipids 
(phosphatidylcholines, usually called “lecithin”) are the main constituents o f liposomes, and 
due to their amphipathic properties, they readily form concentric bilayers. The most common 
laboratory protocol used to create liposomes consists o f  sonication, extrusion, reverse-phase 
evaporation, and solvent injection approaches [20], Depending on their size and the number 
of bilayers, liposomes can be classified into three categories: multi-lamellar vesicles (MLV), 
large uni-lamellar vesicles (LUV) and small unilamellar vesicles (SUV). The major problems 
associated with liposomes are their stability, poor batch-to-batch reproducibility, difficulty in 
sterilization, and low drug loading capacity.
Liposomes and micelles are the most common nano/micro vehicle for delivery o f low 
soluble anticancer drugs; however, their low stability and low 2-3% loading capacity confines
7their application efficiency. In our research, we collaborated with the Pharmacy Department 
o f Northeastern University, the group o f experts who pioneered micellar formulation for 
anticancer drugs (V. Torchilin), and their experience allowed us to understand and exploit 
LbL technique abilities to add new features for nanocapsule formulation (e.g., higher stability, 
and higher drug loading).
1.1.2.3 Dendrimers
Dendrimers are repeatedly branched polymeric macromolecules [19]. Dendrimers have 
three components: an initiator core, branches, and terminal functional groups. The core is 
frequently named (GO) to which are linked first generation monomers (G l), while second 
generation monomers (G2) are linked to corresponding G l monomer in a 2:1 ratio and can be 
properly functionalized coherently with drug delivery application [19], Further steps o f 
generations create the dendrimer and its molecular weight doubles with each additional 
generation. The main advantages o f the dendrimers are (i) nanoscale sizes, (ii) high numbers 
o f  terminal surface groups (Z) suitable for bioconjugation, (iii) an internal hollow space 
which can encapsulate small molecule drugs and (iv) Non- or low immunogenicity due to 
PEGylation.
1.1.2.4 Solid lipid nanoparticles (SLN) and Nanostructured 
Lipid Carriers (NLC)
SLN and NLC have been developed very recently and can be easily synthetized. SLN are 
lipid-based drug-delivery carriers with nanometer to sub-micrometer scale size (50-1000 nm) 
after drug encapsulation; moreover, they have a lipid, biocompatible and biodegradable 
composition and do not require the use of organic solvents for their assembly. The SLN 
particle synthesis protocol, which involves high-pressure homogenization techniques, can be 
performed at a lower cost and can be easily scaled up [20]. NLC, similar to SLN, are 
colloidal particles that typically range in size from 100 to 500 nm. They are composed by 
solid- and liquid-phase lipids, but are generally solid attemperatures above 40 °C. In contrast
8to the lipid crystal matrix o f SLN, the lipid matrix o f NLC has an imperfect crystal or 
amorphous structure. This structure allows for drug loading in both themolecular form and in 
clustered aggregates. Both SLN and NLC have been successfully multi-functionalized to 
target specific cells, and to release drugs in a controlled manner [20]. SLN and NLC 
advantages consist in i) controlled drug delivery and release ii) particularly feasible for 
synergistic multiple drugs encapsulation, and iii) increased blood circulation half time and 
exploiting EPR retention on tumor sites. Hydrophobic drugs with short circulation half-lives 
are ideal candidates for delivery via SLN and NLC [20],
1.1.2.5 Fullerenes and Nanotubes (Carbon nanotubes & Hallovsite')
Fullerenes have a polygonal structure made up by 60 carbon atoms and can be easily 
functionalized. Their diameter is 0.7 nm, but they have a poor solubility in aqueous solvents 
and are likely to create supramolecular aggregates, thus they are hardly used in biomedical 
applications. This problem has been solved functionalizing fullerenes. Amphifullerene 
compounds are functionalized fullerenes, based on a C 6 o core, which contain both 
hydrophobic (water-insoluble) and hydrophilic (water-soluble) moieties, called AF-1 
monomers, and self-assemble to form supramolecular structures referred to as “buckysomes” 
[21]. Buckysomes are self-assembled, water soluble fullerenes used for drug delivery 
approaches, such as the paclitaxel-embedded buckysomes (PEBs). Currently, in vitro and in 
vivo preclinical studies are available, since these structures have not been tested in clinic.
Carbon nanotubes (CNTs) consist o f a single sheet of graphite rolled to form a cylinder 
[16]. CNTs can be used as carriers for the delivery o f drugs, DNA, proteins and other 
molecular probesinto cells [22], Early experimental studies regarding interactions between 
MWNTs and proteins revealed that both biomacromolecules and synthetic molecules can be 
adsorbed over the CNTs' surface [23, 24] and/or fill the internal cavity o f these cargo-carriers
[25].
9For drug delivery, these approaches seem more useful for introducing drugs into interior 
cavity o f tube, whose open ends might be capped to generate a nanopill [25],
However, the main problem of Fullerenes and CNTs as drug nanocontainers is their 
toxicity and low drug encapsulated concentration. We do not foresee practical results based 
on these drug delivery nanosystems.
Halloysite clays are two-layered rolled aluminosilicate, chemically similar to kaolin, 
with hollow tubular structure in the submicrometer range. The size o f halloysite particles 
varies from 50 to 70 nm in external diameter, 15 nm diameter lumen and 1-0.5 pm length
[26]. Their preparation can be made with inexpensive materials and simple protocols of 
fabrication. Moreover, halloysite nanotubes have different chemistry in the inner and outer 
surfaces, and this property can be exploited for different and peculiar modification o f inner 
and outer walls [26], Halloysite nanotubes are much more bio-friendly than carbon nanotubes 
(they are just clay used by people for thousand years); however, again, they are inorganic and 
cannot be used for intravein blood injection because they are not biodegradable.
1.1.3 Drug Delivery Mechanisms
There are mainly two types o f drug delivery mechanisms: 1) passive targeting through 
the enhanced permeability and retention (EPR) effect and 2) active targeting through 
attachment o f special targeting agents. Passive targeting is ubiquitous but it has some 
disadvantages such as low drug delivery efficiency and difficulty in controlling the process. 
The advantage o f Layer-by-Layer self-assembly technology is the wide choice o f materials 
for building up the architectures. Those active targeting agents can be used and incooperated 
into the nanoarchitectures for active targeting to the cancer cells and, therefore, improve the 
efficiency o f cancer treatment and reduce o f toxicity [28],
As can be seen from Figure 1.1 [27], in passive targeting, the vasculature supplying 
cancer lesions might have increased endothelial fenestrations and architectural anarchy,
10
resulting in the preferential extravasations and protracted lodging of injected particulates. The 
active targeting is conjugation o f active recognition moieties to the surface of a nanovector. 
The active targeting requires specific drug delivery system. In our case, the versatility o f 
Layer-by-Layer technology in choosing different compositions for building up the 
nanoarchitechure and the ability to control the size will provide a very powerful drug carrier 
system.
Passive drug targeting Cancer cell targeting
Tumour ^
ET 1 O  |  b]
T v <  ' f l f /Tumour | *  *J *
Normal 8 8 r^ri 
tissue |  I  ILd
Figure 1.1 Passive targeting (left) and active targeting (right) [27]
1.2 M ethodology for M ultifunctional Poorly Soluble D rugs
The application scope o f poorly soluble drugs has been confined due to the difficulty to 
load and control its release target and rate efficiently by conventional techniques. Here, the 
technology gaps and how our technology can solve these problems will be discussed.
1.2.1 Technology Gaps
Poorly soluble drugs are very difficult to load and control its release target and rate 
efficiently. The main gaps for enlarging the application of poorly soluble drugs are listed as 
follows: The first gap is to produce aqueous nanoparticles o f poorly soluble drugs with high 
concentration (more than 50%) of the active drug [28], The second gap is about endowing 
poorly soluble drugs with high targeting selectivity [28] and imaging capability. The third
gap is to simultaneous targeted released and imaged more than one drug or one drug and one 
anti-angiogenic agents at one time. (These drugs can be soluble or poorly soluble).
These three gaps have important theoretic and practical significance for enlarging use of 
drugs and recovery from disease. Because o f the intrinsic poorly soluble property o f many 
drugs, it is thus very difficult to load them and control their release target and rate efficiently. 
Targeting selectivity is mainly concerned with the technology to endow drugs' high 
differential uptake efficiency in the target cells over normal cells via specific ligands [3], 
while the biological solubility, stability and the ability to overcome the barriers are concerned 
with the technology for dissolving insoluble drugs effectively. These two directions are 
interrelated and have some influence on each other towards the purpose o f this research. The 
target selectivity study is important for both soluble and poorly soluble drugs. The 
technology for dissolving insoluble drugs effectively so that they can be as effective as 
soluble drugs is even more important for the commercialization of these drugs, and through 
careful design o f the Layer-by-Layer coating technology, these three goals may be well 
solved. To sum up, they are interrelated and synergistic goals to increase the efficacy of 
poorly soluble drugs, and they all are very important part o f this research.
1.2.2 Laver-bv-Laver Technique
Layer-by-Layer assembly is a unique technique for the fabrication o f composite films 
with nanometer precision. The attractive feature o f this approach is its ability to assemble 
complex structures from modular components, and integrate them into self-assembling 
constructions for a wide range o f applications [29-35],
1.2.2.1 Laver-bv-Laver Approach
As can be seen from Figure 1.2, Layer-by-Layer self-assembly o f multilayer films 
involves the construction o f complex composite materials with precise film thickness, one 
layer at a time, enabling the development o f novel structures and devices with properties
12
tailored by controlling the molecular makeup and arrangement. Early fundamental studies of 
multilayer assemblies on planar substrates demonstrated the practicality and versatility o f the 
approach, and work over the past decade has included further investigation into the internal 
structure and composition o f LbL films, including dynamic and long term interactions 
between film components, solvents, and solute, especially transport properties. Beyond 
assembly onto flat planar surfaces, the multilayer deposition via LbL has been extended to 
colloidal templates, leading to elaborate modification o f particles and even to hollow 
capsules, both o f which are exciting and attractive for many applications. While the bulk of 
work in LbL has been in experimental investigations, some efforts to generate theoretical 
descriptions for the multilayer assembly have also been undertaken, although much more 
work is needed in this area to establish useful models for design of devices based on this 
approach. Finally, applications for LbL films abound and are now being pursued at the 
academic level, with some examples o f industrial applications for eye lens modification, 
improvement o f cellulose fiber for better fabric and paper, microcapsules for insulin 
sustained release, and others [31-35].
Polvcation/polyauion  
bilayer, D= 1 2  nin
Nanoparticle/polvion (or protein) 
bilaver, D = 5-50 nm
Figure 1.2 Layer-by-Layer (LbL) self-assembly ideology [34]
As was demonstrated by Decher et al. [31] in Figure 1.3, Layer-by-Layer self- assembly 
approach consists o f alternate absorption o f polyanions, such as PSS (poly (styrene 
sulphonate)) and DXS (dextran sulphate), and polycations, like PAH (poly (allylamine 
hydrochloride)) and PRM (protamine dextran). The technique takes advantage o f attractive 
electrostatic forces between charged polymers and oppositely charged surfaces, and film 
growth is achieved stepwise by the repetitive exposure of substrates to dilute polycation and 
polyanion solutions.
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Figure 1.3 Layer-by-Layer (LbL) self-assembly set-up and process [31 ]
Hydrophilic and positively charged substrates are immersed into the solution o f 
polyanion (negatively charged polymer, for example, PSS) for several minutes. As a result, a 
thin layer (thickness 1-2 nm) o f the polymer is adsorbed on the surface. Charge 
overcompensation leads to a negative surface re-charging. Then, the substrate is washed (a 
washing step is needed to removenot adsorbed material) and placed into the solution with 
polycation (positively charged polymer, for example, PEI). The polymer is attached 
electrostatically to the charged surface. The process can be repeated several times to reach a 
defined multilayer thickness controlled by layer coating cycling. As depicted in Figure 1.3, 
the iterative dipping o f a substrate (e.g. a glass microscope slide) into solutions o f  oppositely 
charged polyelectrolytes yields multilayered films composed o f alternating layers o f cationic 
and anionic polymers. The thicknesses o f these films typically range from tens or hundreds o f
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nanometers to up to several micrometers, depending on the number o f layers deposited and 
the solution conditions (e.g., pH, ionic strength, etc.) used during fabrication.
This polyelectrolyte multilayer coating can be easily and reproducibly formed on the 
surface o f any charged substrate. By varying the charge density on each polymer or the 
number o f coating cycles, substrates with a different surface charge and different composition 
o f the polymeric coat can be prepared. Layer-by-Layer technique o f assembly permits the 
deposition o f thin films on a wide variety o f macroscopic, microscopic, and nanoscopic 
objects [36-41].
1 -2.2.2 LbL Drug-Loaded Polyelectrolyte Microcapsules
Several groups have used templating Layer-by-Layer assembly to fabricate hollow 
multilayered capsules by depositing polyelectrolytes onto cores that can be dissolved, 
degraded, or otherwise removed after film formation. Experiments are reviewed by 
references [39, 41-49], This approach has been used widely to develop approaches to either 
encapsulate or deliver a wide range o f macromolecular agents. In fact, packaging o f drugs 
into micro- or nanocarriers has sparked great interest on biological validation of 
micro-to-nanoscale delivery systems for targeted therapy [50-51]. For therapeutic purposes, 
there is a clear need to fabricate supramolecular assemblies o f  drug and functional carrier 
materials which would be biocompatible and biodegradable under physiological conditions 
[52-53]. In this respect, hollow microcapsules are of particular interest, as they can be 
fabricated via Layer-by-Layer (LbL) assembly o f  oppositely charged polyelectrolyte 
multilayers o f dextran sulfate (DXS), protamine (PRM) or poly-L-arginine (PLA) that are 
degraded by intracellular proteases or hydrolytic enzymes, around a sacrificial core o f 
calcium carbonate (of few hundred nm to several micrometers o f diameter) that is dissolved 
by EDTA after deposition [54-55], Due to the versatility o f electrostatic interactions, 
properties and functionalities o f the resulting hollow capsules (i.e. their encapsulation or
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release efficiency), can be finely tuned in the nanometer range by varying capsule wall 
thickness and number and composition o f the polymeric layers, hence their permeability in 
response to changes on the pH, ionic strength or solvent [42],
The intrinsic advantage o f LbL fabrication method is unmet by any other technique, as it 
lies in the potential o f entrapping simultaneously drugs, fluorescent probes or colloid 
nanoparticles (e.g. quantum dots or magnetic particles) with tunable functionalities into the 
biodegradable multilayers o f one unique hollow capsule (post-loading method) [42, 56-57].
Polyelectrolyte microcapsules can be fabricated by LbL technique previously described. 
After the consecutive assembly o f oppositely charged polymer layers around the CaCOj core, 
the core itself is removed to obtain hollow and stable capsules whose inner cavity and 
polymer wall can be loaded and functionalized, respectively, with a variety o f substances 
such as molecular dyes, drugs, biomolecules, which retain their distinctive properties after 
the embedding procedure [49, 58]. The resulting hollow capsule usually has a wall thickness 
o f between a few tens and several hundred nanometers and have a diameter ranging from tens 
o f nanometers to several micrometers, depending on the size o f the original core [49, 58], 
The forming of the hollow capsule is illustrated in Figure 1.4.
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Figure 1.4 Formation and release o f LbL assembly capsules [58]
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Particularly, the initial step of nanoparticle formation is the creation o f CaCCL core 
mixing soluble salts o f Ca2 , as CaCL, and CO 3 2' compounds, like Na2 CC>3 . The mixture 
results in an amorphous precipitate initially, which subsequently transforms into aggregated 
CaCC>3 microcrystals with a particular morphology. The CaCCL microparticles obtained by 
this simple route are uniform and homogenously sized, non- aggregated, high porous spheres. 
The quality o f the resultant microparticles was found to be strongly dependent on the 
experimental conditions such as type of salts used, their concentration, pH values, 
temperature, and rate o f solution mixing and intensity agitation of the reaction mixture [59, 
60], After core building, the LbL covering occurs, using an alternate layering o f polyanions 
and polycations (DXS-PRM and PSS-PAH). Once a multilayered layer has been created, 
CaC 0 3  core dissolution occurs by saline solutions (e.g. sodium hypochloritesolution) or 
ethylenediaminetetraacetic acid (EDTA). The core dissolution makes an empty cavity, 
subsequently loaded with a drug, like paclitaxel. Two fundamental components for capsule 
fabrication are the core templates and the polyelectrolyte pairs. An ideal template has to be 
stable under the LbL process, soluble in mild conditions and completely removable from the 
inside o f the capsules without affecting the morphology and stability o f the multilayer 
assembled on top o f it. In recent years, numerous materials have been employed as sacrificial 
templates such as polystyrene latex, melamine formaldehyde (MF), SiCL, carbonate particles 
(MnCCL, CaCCL, CdCCL) and biological cells like erythrocytes [49, 58], The assembly of 
Latex is shown in Figure 1.5 as an example.
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Figure 1.5 LbL assembly o f Latex [34]
The capsule wall is also crucial for the fabrication o f  functional capsules, as their 
permeability or porosity strongly depends on the chemical structure and the molecular weight 
o f the employed polyelectrolyte pairs. The majority o f  polyelectrolyte capsules described in 
literature are composed o f pairs o f synthetic biocompatible-not-biodegradable 
polyelectrolytes such as anionic poly (sodium) styrene sulphonate and cationic poly 
(allylamine) hydrochloride, or composed o f biocompatible and biodegradable 
polyelectrolytes such as dextran sulphonate and protamine sulphate, which are more suited 
for therapeutic use. The mechanical/elastic properties o f  polyelectrolyte capsules are 
influenced byseveral parameters such as the chemical nature o f  the polymer used, which can 
cause weak or strong intermolecular interactions with the multilayer, and the molecular 
composition o f the innerpart o f the capsules [54],
LbL deposition onto charged polystyrene (PS) particles in solution was firstly exploited 
by Caruso and co-workers [54] to construct hollow polyelectrolyte shells through the
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stepwise adsorption o f polyelectrolytes onto a decomposable colloidal template. This 
template was subsequently removed after formation o f the multilayer shells was realized. 
Instead o f PS particles weakly cross-linked melamine formaldehyde (MF) colloidal particles 
were used by Donath et al. [55], These particles decompose in aqueous media at pH values 
below 1.6. The PSS/PAH polyelectrolyte multilayer film was built up beginning with 
adsorption o f the negatively charged polyelectrolyte onto the positively charged MF particles. 
When these coated MF particles were exposed to low pH, the core decomposed [55], and the 
residual MF oligomers were expelled from the core, since they could permeate through the 
polyelectrolyte layers that form the shell. These MF oligomers were separated from the 
hollow shells by centrifugation. MF particles are widely used as core templates and have 
been very well characterized. They are favored above PS particles because o f their 
decomposable character but have several disadvantages, such as their low biocompatibility. 
Furthermore, the oligomers formed after decomposition can partially remain inside the 
polymer wall during the dissolution process, and there is an increased resistance or difficulty 
to decomposition upon time. In order to overcome these disadvantages, other biocompatible 
and decomposable templates for LbL techniques have been investigated [61]. The two mostly 
studied template materials are poly-DL-lactic acid (PDLA) and poly (DL-lactic-coglycolic 
acid) (PLGA). Degradable microparticles based on these biopolymers were prepared using 
the oil/water emulsion-solvent evaporation technique. PSS and PAH were chosen as 
polyelectrolytes to coat onto the biodegradable templates. The next step was the removal of 
the core by dissolution, which was achieved by dissolving the polymers in a mixture o f 
NMP/acetone in a 1:1 volume ration [61], Instead o f an MF core, metal carbonate crystals 
were also used by Ma et al. [62], These cores can be removed easily by EDTA solution. The 
advantage o f using these organometallic polymers for incorporation into the capsule walls is 
that they allow changing the permeability o f these walls. The CaCCL template particle has
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found use for encapsulation o f  biological compounds, since it can be dissolved under healthy 
conditions.
1.2.2.3 LbL Drue-Loaded Polyelectrolyte Nanocolloids
A natural extension o f previously described approach is the deposition of polyelectrolyte 
films on nanoparticles (drug or inorganic) leading to coated nanocolloids. In this respect our 
group developed recently drug-nanocolloids [63], These novel entities are stable aqueous 
polyelectrolyte multilayer shells built on drug particles with few nanometer wall thicknesses 
(up to 100 nm) and made through a LbL assembly, which consisted in an alternate adsorption 
o f oppositely charged polyelectrolytes onto solid templates [63]. LbL coating technology was 
used to make stable aqueous nanocarriers o f poorly soluble drugs with a high content o f the 
active drugand controllable drug release rate. To achieve this goal, aqueous suspensions of 
poorly soluble drugs with micron range particles are subjected to the ultrasonic treatment in 
order to decrease the size o f individual drug particles to the nano level (between 100 and 200 
nm), while keeping the nanoparticles formed under the sonication to prevent their fast 
agglomeration, stabilize them in solution by applying the LbL coating (alternating addition of 
polycations and polyanions to the system) and assembling thin polyelectrolyte shells on their 
surface. In the assembly process, the highly charged polymeric layer was formed on the drug 
particle surface after the first polymer application, and this layer prevents drug particle 
aggregation after terminating the sonication. At the end o f the process, stable coated 
nanocolloidal drug dispersions were formed with high drug content in each particle (between 
50% and 90%) [63]. Moreover, it wa also possible to functionalize nanocolloids using a 
polymer containing reactive groups (such as amino orcarboxylic groups) for the last “outer” 
surface layer, thus allowing the linking o f specific ligands, or reporter groups, and other 
moieties o f interest to drug nanoparticles such as monoclonal antibodies [63].
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1.2.3 Sonochemistry
One o f the central problems for LbL nanoformulation is formation o f the initial drug core 
o f 200-300 nm in diameter. We solved this problem with bulk drug ultrasonication with 
simultaneous polycation deposition stabilizing formed dispersion. Sonochemistry will enable 
“green” chemistry without environmentally harmful chemical by-products. Compared to 
different sources o f the energy input into the reaction, ultrasonic treatment can induce a wide 
range of chemical reactions in non-equilibrium state applicable for synthesis and 
modification o f products with new physico-chemical characteristics and catalytic activity. 
The effects o f ultrasound derive primarily from cavitation, where bubbles collapse in liquids, 
which results in an enormous concentration o f spatially confined energy. This energy is 
derived from the surface and kinetic energy within the liquid converted into heat and 
chemical energy imparted to resulting materials [64-66]. Nanoparticle synthesis is often 
based on control o f nucleation and crystallization [67-69], The vision o f the proposed project 
was to achieve a breakthrough in ultrasonic synthesis by employing surface-active materials 
(amphiphilic polymers, polyelectrolytes, surface-functionalized nanoparticles, etc.) as 
regulators to control the interfacial parameters o f the cavitation process on nano level during 
formation and collapse o f microbubbles. Introducing the surface-active materials at the 
cavitation interface will enable one to control the temperature and pressure inside bubbles, to 
control the energy balance and ways o f energy dissipation. The proposed approach will help 
in controlling the structure and physical state o f the cavitation interface and develop new 
methods for one-step sonochemical synthesis o f  nanoparticles with core-shell structures.
Figure 1.6 is the set-up for sonication study. Ultrasonication can be applied to create 
extreme physical-chemical conditions at the liquid/gas interface; whereas, the bulk solution 
can stay at room-temperature.
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Figure 1.6 Set-up for sonication study [66]
During high-power ultrasonication (20 kHz, 50-100W), gas bubbles were formed and 
expanded, followed by cavity implosion and je t formation (Figure 1.7).
Figure 1.7 Cavity implosion and jet formation [66]
The cavity implosion created very high temperature (up to 5000 K) (Figure 1.8) and high 
pressure (up to 103 atmosphere) in the center o f the cavity, while the bulk solution remained 
at low-temperature because o f  localized energy release and high cooling rate. This high 
pressure and the jet formation crushed solid materials into micro- and nanoparticles [64-68],
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Figure 1.8 Cavity temperatures [66]
Figure 1.9 schematically illustrates the control mechanism over cavitation process. Initial 
mixture contains initial reagents and surface-active materials with regulated 
hydrophobic/hydrophilic balance. During ultrasonic treatment and formation o f microbubbles, 
these materials go to a liquid/gas interface changing the surface energy o f  the microbubble 
and, as a result, final energy and its partition ratio (between thermal and chemical) during 
microbubble collapse [64-70],
Control over:
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so n o lu m in escen ce , 
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Figure 1.9 Schematic illustration o f cavitation process
In our study, sonication was performed in the presence o f surface-active agents to ensure 
their adsorption at the cavitation interface. These surface-active agents had the effect of 
stabilization and to increase o f the lifetime o f the cavitation microbubble up to second range 
(Figure 1.10).
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Figure 1.10 Lifetime of the cavitation microbubble [66]
The precursor reagents (bulk materials, monomers, and colloids) were added after 
starting the sonication in the presence o f already adsorbed surface-active material (Figure 
1 . 1 1 ).
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Figure 1.11 Adsorptions o f surface-active materials onto the nanocolloids
To sum up, there were mainly three effects power sonication had: cavity with high 
temperature, jet flow generated after cavity collapse, and polyelectrolyte enrich on the cavity 
surface.
In order to attempt to decrease the diameter o f the formed nanocores o f paclitaxel, we 
developed two experimental techniques to increase energy o f bubble collapsing (bubble 
formation enhancers) and elevated gas pressure which will be described further.
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1.2.4 Methodology r70-751
We used paclitaxel and lapatinib as representative poorly soluble anticancer drugs and 
aimed at establishing a simple, effective method which can be helpful for yielding advances 
in early detection, diagnostics, prognostics and the selection o f various therapeutic strategies.
Our project focused on the study on ultrasonication assisted Layer-by-Layer technique 
for preparing multifunctional paclitaxel and lapatinib nanoparticles. Figure 1.12 shows the 
methodology. First, powerful ultra-sonication was applied for making small drug 
nanoparticles o f  desired size and suitable shape. Second, the Layer-by-Layer self-assembly of 
multilayer films was applied for building up the novel structures with properties tailored by 
controlling the molecular makeup and arrangement with nanoscale precise film thickness. In 
this process, a nanoarchitectural approach designing layers o f different components, 
including ones serving as diffusion barrier and outermost layers containing targeting agents, 
can be realized. Third, the well prepared drug nanocolloids were delivered to the cancer cells 
for treatment o f cancer.
Figure 1.12 Methodology
1.2.4.1 Preparation of Hydrophobic Drug Particles with 
Desired Size and Suitable Shape
Our first step was to prepare hydrophobic drug particles with desired size and suitable
shape. Powerful ultra-sound generates micro-bubbles in liquid. These micro-bubbles will
Nanocolloids (i.e. 
an ticancer drug)
idivery of Nanoccrriers into Cancer Cells
Cellular death  (A poptosis)
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collapse in microseconds. If any solid particle is near the bubble, jet fluid and shock waves 
will hit the particle and break it during collapsing [64-75]. The particle will have a wide 
range o f size since the ultrasonic process for breaking down the particles is a mechanical 
process. Sonication power and time both have effect on the particle size distribution. In 
general, higher power and longer time will result in smaller particles. While adding 
polyelectrolyte into the solution, the negative surface o f the newly formed surface will help 
keep particles away from forming aggregation. Thus smaller particle size can be achieved 
with better size distribution. Polycations were added during the sonication process to adsorb 
drug nanoparticles and were thus prevented from re-aggregation. Surface potential of 
particles will become more positive during this process for the influence o f polycations.
1.2.4.2 Design and Implementation o f the Layer-by-Layer 
Coating Technology
Different number o f layers and different polyelectrolyte types will affect the drug release 
rate. To obtain sustained release, the coating structure needs to be carefully designed (to 
obtain optimum release property). An anti-angiogenesis agent such as combretastatin-A4 will 
also be coated as a layer outside the core drug layer which is expected to be released before 
the drug to stop the cancer cell from growing larger. After that, we will use the LbL 
technology to efficiently bind drug nanoparticles to special targeting ligands to kill cancer 
cells. We will carefully design the coating structure to obtain the optimum release property. 
The outside layer will be coated with magnetic particles to target delivery and trace the drug 
particles to specific cancer cells.
1.2.4.3 PEGylation and Controlled Release Study
To further improve our DDS for cancer treatment, stealthy (PEGylation) technology was 
carried out for increased solubility, stability and drug circulation time. The formula for PEG 
is HO-(CHCHO) n -CHCH-OH. A controlled release study has also been carried out.
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Our research is superior to micelle carrier and other drug delivery techniques in 
universality o f method (for micelle carrier technology, different drugs require different 
condition to become soluble), drug concentration (more than 50% compared with less than 
5%), release rate (easy and difficult controllability), and stability (high and low), and 
simultaneously release o f more than one drugs.
1.3 O utline
Chapter One introduces the motivation and some background information o f this 
research work. It also gives a brief literature review covering the knowledge needed for this 
dissertation: cancer treatment and drug delivery systems, LbL nanoassembly, and 
sonochemistry. Our methodology for multifunctional poorly soluble drugs is shown. The 
research goals and the organization o f this dissertation are discussed as well. Chapter Two 
describes materials and instruments used for the research. Chapter Three discusses the 
top-down approach and bubbling agent approach for preparing paclitaxel nanocores. Their 
optimization processes are also presented. Chapter Four describes the bottom-up approach for 
preparing paclitaxel and lapatinib nanocores (first concentrated solutions o f  these drugs were 
dissolved in DMSO or alcohol to make molecular solution, and then controlled nucleation of 
drugs were induced by water addition to decrease the solubility). The surfactant additives 
arrest growths o f the formed cores, allowing the formation of drug particles with the 
diameters in the range o f 150-200 nm. Chapter Five demonstrates colloid stabilization with 
the PEGylation and controlled release study o f those drug nanocolloids using adjustment of 
polyelectrolyte layers in the shells. Chapter Six describes the dual drugs encapsulation 
paclitaxel and lapatinib. Chapter Seven concludes the results o f  the dissertation. Some issues 
and topics for future work are recommended and a list of publications and presentations on 
this work are given.
CHAPTER 2
MATERIALS AND INSTRUMENTS
2.1 M aterials
The two low soluble drugs, paclitaxel and lapatinib were purchased from LC 
Laboratories, Inc. (Woburn, MA).
There are two types o f polyelectrolytes used for Layer-by-Layer self-assembly: 
polycations and polyanions. Poly (dimethyldiallyl ammonium chloride) (PDDA), 
Polyallylamine hydrochloride (PAH) are used as highzeta-potential polycations. Polylysine
(PLL), PEGylated poly lysine (PEG-b-PLL), Protamine sulfate ( PS )and Chitosan are used as
biocompatible polycations. Poly (acrylic acid) (PAA), Sodium polystyrene sulfonate (PSS) 
are used as highzeta-potential polyanions. Alginic acid (AA), Heparin, Bovine serum 
albumin (BSA), and Chondroitin sulfate (CS) are used as biocompatible polyanions. They are 
used at the concentration range from 1-3 mg/mL. All polycations and polyanions were
bought from Sigma-Aldrich. PBS buffer, DMSO, NH4HCO3, Ethanol, Acetone, FITC ,
TWEEN 80 and PVP were also purchased from Sigma-Aldrich.
Reagents and Cell culture for dual drug study: The PI3K. inhibitor, LY294002, and the 
ERK 1/2 inhibitor, U0126, were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). Rhodamine (TR1TC) conjugated phalloidin, were purchased from Sigma-Aldrich. The 
antibodies against cofilin, p-cofilin (ser-3), Akt, pAkt (ser 473), cyclin D1 and Tubulin were
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purchased from Santa Cruz Biotechnology. Inhibitors for PI3K and ERK, paclitaxel were all 
dissolved in DMSO.
The ovarian cancer cell line OVCAR-3 and the breast cancer cell line MCF-7 were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal 
bovin serum, 2 mM glutamine, lOOU/ml penicellin and 100 pg/ml streptomycin, and cultured 
at 37° C in a humidified atmosphere o f 5% CCE. Cells were subcultured every three days.
2.2 Instrum ents
2.2.1 Ultrasonicator
A UlPlOOOhd Ultrasonicator (Heilscher, Germany) (Figure 2.1 (a)) was used as powerful 
ultrasonicator. It came with a titanium sonotron and its working power was 15 W /cnr.
A Branson 1510 Ultrasonicator (Figure 2.1 (b)) was used as a standard ultrasonicator. An 
ice/water mixture was used as a cooling agent during ultrasonication. During ultrasonication, 
the ambient temperature is cooled down by the ice/water mixture.
Figure 2.1 (a) powerful ultrasonicator (power: 15 W/cm2) (b) standard ultrasonicator 
2.2.2 Centrifuge
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An Eppendorf Centrifuge 5804R (Figure 2.2) was applied for centrifugation o f drug 
nanoparticles.
Figure 2.2 Centrifuge
The centrifugation speed range is from 0-15,000 rpm (rotate per minute). Generally, 
2000 rpm was applied for precipitation o f bigger particles (size larger than 500 nm) for 10 
minutes. Centrifugation at 12,000 rpm for 10 minutes was applied for the separation o f the 
drug nanoparticles from the solution (solvent, additional polyelectrolytes, surfactants and so 
on).
2.2.3 ZetaPlus Microelectrophoresis Equipment
ZetaPlus Microelectrophoresis equipment (Brookhaven) (Figure 2.3) has been applied 
for the measurements of particle size and £ (zeta) -potential. Successful sequential coating
o f oppositely charged polyelectrolytes can be measured by the electrical surface ^-potential
changes.
Figure 2.3 ZetaPlus microelectrophoresis equipment
Figure 2.4 shows the mechanism for Zeta potential. Zeta potential refers to the 
electrostatic potential generated by the accumulation o f ions at the surface o f a particle. For 
determining zeta potential, a controlled electric field is applied via electrodes immersed in the 
sample suspension, and this causes the charged particles to move towards the electrode of 
opposite polarity. Viscous forces acting upon the moving particle tend to oppose this motion 
and equilibrium is rapidly established between the effects o f the electrostatic attraction and 
the viscous drag. The particles, therefore, reach a constant "terminal" velocity. This velocity 
is dependent upon the electric field strength or voltage gradient, the dielectric constant and 
viscosity o f the liquid, all o f  which are known, and the zeta potential. It is usually expressed 
as the particle mobility which is the velocity under unit field strength. In practice, zeta
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potentials are usually negative (i.e. the surface is negatively charged), but they can lie 
anywhere in the range from -100 to +100 mV.
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Figure 2.4 Mechanism for Zeta potential (From ref. 74)
2.2.4 Light Scattering Detectors
Precision detectors PDExpert Light Scattering Workstation (Figure 2.5) was also applied 
to double check the particle size.
Figure 2.5 Precision light scattering detectors
The workstation provides molecular size and conformation data from the autocorrelation 
of dynamic light scattering signals at any user-selectable angle in five degree increments on a 
360° platform. It is also known as quasi-elastic light scattering (QELS) or photon correlation
spectroscopy (PCS). It can be applied for the recording o f the scattered light intensity 
changes on ps time range for individual particles' Brownian motion. It is quantified as an 
exponential function under the assumptions o f low concentration, spherical size particle and 
known viscosity o f its environment.
It provides accurate measurements for hydrodynamic radius (Rh) and hydrodynamic 
radius distributions from any type o f sample ranging from molecules (protein and antibody) 
to nanoparticles such as liposomes, sols, magnetic particles, emulsions etc.
2.2.5 Confocal Microscope
A Leica TCS SP2 laser scanning confocal microscope (Leica Microsystems, Inc.) 
(Figure 2.6 ) was applied for visualization o f the fluorescent FITC labeled onto the outmost
polycation layer o f the drug nanoarchitechure for the shell composition confirmation.
Figure 2.6 Confocal Microscope
Confocal microscopy has been widely used in the investigations o f biological and 
medical thin optical specimens imaging for thickness up to 100 pm. The confocal 
microscopy is equipped with several high-speed acousto-optic tunable filters (AOTFs) laser
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systems. Therefore, it can have excellent wavelength and excitation intensity regulation. Its 
minimum detectable size is around 400 nm.
2.2.6 Scanning Electron Microscope
A Hitachi S 4800 FESEM (field emission scanning electron microscope) (Figure 2.7) 
was used for particle morphology imaging and size measurement. Prior to imaging, 
De-Ionized water was used to wash samples for three times. Samples were then diluted 10 
times and put onto silicon wafer. When the samples were dried, they were applied for 
imaging. An EDX detector included in the FESEM can be applied for the element 
composition analysis.
Figure 2.7 FESEM
2.2.7 X -ray D iffractom eter (XRD )
A Bruker D8 Discover XRD (X-ray diffractometer) (Figure 2.8) machine was applied for 
non-destructive crystal structure and chemical composition determination o f  drug samples. 
The XRD is a tool for the observation samples by detecting the scattered intensity after being
hitted by X-ray beam. The XRD measurement is based on the Bragg's law: 2d sin0=n/L For 
the function, 0, X and d are the scattered angle o f the X-ray, wavelength o f the X-ray 
and d-spacing o f the sample resepectively. The d-spacing is the distance between crystalline 
planes, which gives information about the sample.
Figure 2.8 XRD
2.2.8 UV Spectrophotometer
An Agilent 8453 UV spectrophotometer (Figure 2.9) was used for detection o f the drug 
concentration. Its applicable wave length is from 190 to 1100 nm. For those low soluble 
drugs, paclitaxel absorbance was measured at 245 nm in Ethanol and PBS. Lapatinib 
absorbance was measured at 365 nm in DMSO and PBS/TWEEN 80.
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Figure 2.9 UV spectrophotometer
2.2.9 Release Chamber
The release study o f those drug nanoparticles was carried out using two 1 ml standard 
horizontal diffusion chambers (Figure 2.10). There are mainly five components o f the 
diffusion chambers as listed in Figure 2.9. In between these two diffusion chambers, 0.2 pm 
pore size acetate membranes are used for the diffusion of drug molecular. In each diffusion 
chamber, a magnetic stirrer was put inside for the uniform dispersion o f drug nanoparticles. 
The whole release set-up was placed on a magnetic stirring system, and then 1 ml o f drug 
dispersion was added into one side o f the chamber, while 1 ml of PBS was added into the 
other side o f the chamber. After a certain time period, the drug molecular diffused onto the 
PBS side was taken by 1 ml pipette and put into quartz cuvette for UV absorbance 
measurement. One milliliter o f fresh PBS was then being put back into the chamber for the 
diffusion test.
Figure 2.10 Release Chambers (1) 1ml horizontal chamber; (2) magnetic stirrer; (3) chamber 
side; (4) 0.2 pm pore size acetate membranes; (5) chamber entrance for drug dispersion 
add-in.
CHAPTER 3
TOP-DOWN APPROACH FOR PREPARING 
PACLITAXEL NANOCORES
In this chapter the top-down approach is described. Some sections o f this chapter were 
published in a paper written by the author o f this dissertation in co-authorship with Dr. 
Lvov and others as “Converting Poorly Soluble Materials into Stable Aqueous Nanocolloids” 
in Langmuir, 2011, 27 (3), 1212-1217. The text sections cited from this paper is properly 
cited as [72], and they are not in use in any other dissertation.
Ultrasonication can be applied to create extreme physical-chemical conditions at the 
liquid/gas interface, whereas the bulk solution can stay at room-temperature. During 
high-power ultrasonication (20 kHz, 50-100 W) gas bubbles are formed and expanded, 
followed by cavity implosion and je t formation. This creates very high local temperature (up 
to 5000 K) and high pressure (up to 103 atm) in the center o f  the cavity, whereas the bulk 
solution remains at low-temperature because o f localized energy release and high cooling rate. 
This high pressure and the jet formation crush solid materials into micro- and nanoparticles 
[27-31],
In this chapter, the top-down ultrasonication approach for preparing paclitaxel 
nanocolloid will be discussed as a representative method developed for preparing small size 
low soluble drug nanocolloid. The chemical structure o f paclitaxel is shown in Figure 3.1.
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Figure 3.1 Chemical structure for paclitaxel
3.1 Top-D ow n A pproach
Figure 3.2 shows the scheme for top-down approach. In this process, ultrasonication was 
applied to break down crystal structure o f  paclitaxel into nanoparticles while they are coated 
with polyelectrolyte to provide the system colloidal stability. Oppositely charged 
polyelectrolytes were applied one layer at a time for the prevention o f recrystallization o f 
those nanoparticles.
S o r u c a t o r
p r o b e
In s o lu b le  o rg a n ic  c o m p o u n d  
c r y s ta l  in d is tilled  w a te r
■ S jsn ic su o o ■■
* •
•  *  *  
*  •  *  m
Drug nanorwrticles
w e r e  s ta b i liz e d  b y  
a d d itio n  o f  e s lx c a U o n
F o rm a t io n  o f  th e ■
s e c o n d  la y e r  b y  th e
• D Q iyan ion * m l
•  •  •• •  •  •  _ • • • • i• • •  • • ♦  9  9m m
Figure 3.2 Scheme for top-down approach [72]
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To be more specific, 0.5 mg/ml o f paclitaxel crystal were added into De-Ionized water, 
and then ultrasonication with 15 W/cm" in power was applied for 45 minutes. Due to the 
negative surface ^-potential o f the drug particle, polycation (positive polyelectrolyte such as 
chitosan, protamine sulfate and polylysine) was added to the solution during ultrasonication 
was continuously adsorbed onto the particle surface during the crystal broken down process 
providing enhanced surface potential. During this process, ca. 300 nm size drug particles 
coated with a layer o f polycation were obtained.
A set o f experiments had been done to figure the minimal amount o f polyelectrolyte 
necessary for surface recharging and further Layer-by-Layer shell build up. This minimal 
polyelectrolyte amount minimized the non-reacted polyelectrolyte remaining in bulk solution. 
Then oppositely charged polyanions (negative polyelectrolyte such as heparin, albumin and 
alginic acid) whose surface charge is opposite to the previously coated layer, was added into 
the solution with extended 15 minutes ultrasonication. This process o f sequential adsorption 
o f oppositely charged polyelectrolytes while preserving ultrasonication was repeated three to 
five times for stable nanocapsule formation with desired nano-architecture and functionality. 
Compared with the conventional Layer-by-Layer process, we minimized those tedious 
processes o f washing and centrifugation to form a washless Layer-by-Layer process. After 
the completion o f the Layer-by-Layer coating process, the paclitaxel drug dispersions were 
centrifuged at 12,000 rpm for 10 minutes to remove the excess polyelectrolytes. They were 
then washed and re-suspended in De-Ionized water for further experiments. The electrical 
surface q-potential and size o f the nanocolloids measurements were performed using 
ZetaPlus microelectrophoretic instrument and light scattering machine. These machines 
characterized the success (or failure) o f the Layer-by-Layer coating. FESEM and laser 
confocal microscopy imaging was applied for morphology characterization.
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3.2 Top-Down Approach with Bubbling Agent
As described in Chapter One, the additions o f chemicals which can produce more gas 
microbubbles increase the efficiency of ultrasonication. Figure 3.3 shows the SEM image of 
paclitaxel before and after top-down approach. As we can see from Figure 3.3 (a), the 
original paclitaxel are several microns in length. In Figure 3.3 (b) and Figure 3.3 (c), after the 
process using top-down approach, we were able to get paclitaxel nanoparticles around 300 
nm in size. The nanoparticles have the good property o f narrow size distribution. However it 
is very difficult to break the particle size down to less than 300 nm in size using the top-down 
approach. This difficulty may confine its medical application for the small size requirement.
[ » «rwt
(a) (b) (c)
Figure 3.3 SEM image o f paclitaxel before and after top-down approach, (a) Original 
paclitaxel; (b-c) Top-down sonication method (paclitaxel/(chitosan/alginic acid) 2 ).
Figure 3.4 confirms the SEM result of paclitaxel nanoparticles after top-down approach 
with bubbling agent using Precision detectors PDExpert light scattering workstation. It shows 
that the paclitaxel nanoparticles coated with PAH/PSS had an average size o f 120 ± 30 nm 
obtained with LbL ultrasonication enhanced with bubbling agent NH4HCO3 used at 
concentration 1 mg/ml. This result also shows its narrow particle size distribution.
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Figure 3.4 Light scattering result o f  paclitaxel after top-down approach with bubbling agent 
(X-axis: size in nm, Y-axis: ratio o f  particles o f certain size as compared to the total particles)
Figure 3.5 shows the SEM result for using bubbling agent on large scale. We can clearly 
see particle size uniformity (assuming that singe particle circles form these rings).
Figure 3.5 SEM image for paclitaxel nanocores formation with bubbling agent enhancement
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3.3 Zeta Potential Monitoring the LbL Process
The best way to monitor the Layer-by-Layer process is to control the reversal change of 
the particle surface potential changing during the process o f alternate adsorption and coating. 
As can be seen from Figure 3.6, 2,-potential o f  original paclitaxel crystal was found to be 
-20mV. Without the Layer-by-Layer coating, initial nanocolloids were stable only during 
sonication; however, aggregation came quickly when the power sonication was terminated. 
Therefore the Layer-by-Layer coating was applied for better stability. In the first trial for 
Layer-by-Layer coating, we applied synthetic polyelectrolytes (polycation: poly (allylamine 
hydrochloride) (PAH) and polyanion: poly (styrene sulphonate) (PSS)) since they have higher 
ionization and surface charge which help in anchoring on nanocolloids. This synthetic 
polyelectrolytes coating process is a common way for Layer-by-Layer study and had been 
applied in industry. After the process was elaborated, we began to use biocompatible 
polyelectrolytes (polycation: chitosan, polyanion: alginic acid) since for real biomedical 
application we need our drug formulation to be biocompatible and biodegradable.
PAH
30
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Figure 3.6 2,-potential monitoring o f the Layer-by-Layer process for the nanocolloids for 
synthetic and natural biodegradable polyelectrolytes
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Figure 3.6 shows the alternate change in surface ^-potential o f the drug nanoparticles 
during the adding o f each polycation and polyanion solution during permanent sonication. 
The first polycation layer o f poly (allylamine hydrochloride) (PAH) switched the surface
^-potential to 30 ± 3 mV, higher than that o f biocompatible chitosan at 24 ± 2 mV. The
following first polyanion layer o f poly (styrene sulphonate) (PSS) switched the surface 
^-potential back to -47 ± 3 mV, more negative than that o f  biocompatible alginic acid at
-35 ±3 mV. Both the adsorption o f polycation and polyanion layer was continued and showed 
the regular electrical potential reversal. The changes in potential proved the successful 
coating o f Layer-by-Layer technology. And this worked also for both natural biodegradable 
polyelectrolytes chitosan and alginic acid.
Figure 3.7 shows the chemical structure for chitosan and alginic acid used. Their 
biocompatibility and biodegradability have been helpful in cell experiment and human study. 
The successful coating with synthetic and biodegradable polyelectrolytes shows the 
versatility o f materials choice for building up the architecture using Layer-by-Layer 
technology.
Figure 3.7 Chemical structure for biocompatible polyelectrolytes: (a) polycation: chitosan (b) 
polyanion: alginic acid
After the three to four bilayers coating with these polyelectrolytes, drug nanocolloids can 
be stable for at least one week without essential aggregation (no sediments).
HOCH,
(a) polycation: chitosan (b) polyanion: alginic acid
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For biocompatible polyelectrolytes, we also tried combinations o f  peptides and proteins 
(positive protamine sulfate (PS) and negative bovine serum albumin). The shell made o f 
chitosan and alginic acid showed better colloidal stability than protamine sulfate and albumin 
combination which aggregated in two days. The better stability is due to their higher surface 
potential since after the final alginic acid layer coating, the nanoparticle reached the value 
more (in magnitude) than -30 ± 3 mV. which is considered as a threshold o f stable colloid 
formation. Therefore, the optimization o f the shell architecture for better stability was
important. This surface ^-potential characterization showed similar result for the similar
architecture shell samples with and without bubbling agent, but bubbling allowed smaller 
initial nanocore formation.
3. 4 Confocal Fluorescence Image
Figure 3.8 shows the confocal fluorescence image for the paclitaxel nanoparticles coated 
with PAH and FITC-labeled PSS by top-down approach. We understand that we do not see a 
real image of the particle because it is smaller than the confocal microscope resolution 
(500nm). With this image, we just want to demonstrate that our paclitaxel nanocolloid is well 
dispersed and non-aggregated (so each separate particle image is smeared due to the 
convolution with instrumental function).
J uki
Figure 3.8 Confocal fluorescence image for top-down approach
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3.5 Efficiency of Bubbling Agent Method
An important question is: what is the chemical stability o f the samples under high local 
spot temperature in oxygen-saturated solutions and with the existence o f bubbling agent? We 
needed to prove the final outcome for the bubbling agent method to be not de-composed 
paclitaxel. X-ray diffraction (XRD) had been applied for study o f  the crystalline structure of 
the final LbL shelled nanocolloids.
Hypothesis: The bubbling agent added during the process o f sonication will evaporate 
and will not have an effect on the composition o f the final outcome, that is, the final outcome 
is still paclitaxel.
Methodology: Use XRD to identify crystalline structure o f  the final output o f bubbling 
agent method with pure paclitaxel and to compare it with crystal structure o f the original bulk 
paclitaxel.
Result: The XRD result is shown in Figure 3.9. The XRD measurement is based on 
the Bragg's law: 2d sin0=nL For the function, 0, X and d are the scattered angle o f the X-ray, 
wavelength of the X-ray and d-spacing o f the sample resepectively. The d-spacing is the 
distance between crystalline planes, which gives information about the sample. The bottom 
curve shows the information o f the 20 peaks o f pure paclitaxel. The top curve shows the 
information of the 2 0  peaks o f final outcome o f  bubbling agent method. It can be clearly seen 
from Figure 3.9 that the peaks o f the two samples overlap well with each other. According to 
the Bragg's law, they have the same d-spacing, which gives information about the sample. 
The overlap means that the final outcome of the bubbling agent method is paclitaxel.
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Figure 3.9 The XRD results o f pure paclitaxel (bottom curve) and the final outcome of 
bubbling agent method (top curve)
Conclusion: The bubbling agent added during the process o f sonication does not have 
any essential effect on the composition o f the final outcome. The final outcome is still 
paclitaxel.
3.6 Mechanism of Bubbling Agent for Enhancement 
of Ultrasonication Capability
To maximize the ultrasonication capability for nanoparticulation, the bubble nucleation 
rate is a key parameter. Using NH4HCO3 as a bubbling agent to enhance bubble nucleation 
allowed us decreasing size o f colloid particles closer to 100 nm (Figure 3.3(d)). To be 
specific in experiment, NH4HCO3 had been dissoled in the first polycation solution and then 
added into the drug solution during sonication. This bubbling agent was completely
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decomposed and "bubbled-out” during sonication as NH3 and CCT gases. The size
distribution diagram was centered at 1 2 0  nm and its width is 60 nm.
Figure 3.10 shows the result for top-down method with bubbling agent. Its average size is
120 ± 30 nm. It is much smaller than without bubbling agent.
Figure 3.10 SEM image o f paclitaxel coated with PAH/PSS with average size o f 120 ± 30 nm 
obtained with top-down LbL ultrasonication enhanced with bubbling agent NH4HCO3 used at 
concentration 1 mg/ml [72],
Besides the gas concentration in solvent, the bubble nucleation rate dN/dt depends on gas 
concentration, temperature, surface tension, pressure, hydrophobicity o f the substrate surface 
[30]:
dN/dt = Constant * c * exp(-AE/kT). (Eq. 1)
Here c is gas concentration, AE = 4 7 uo3 P' 2  g(0)/3 is the energy barrier for the bubble 
nucleation, T is the surrounding temperature, a  is the liquid/air surface tension. P is pressure; 
0  is the contact angle o f the surface.
Since we used an aqueous medium for the nanocolloid synthesis, there was a minute 
variation for surface tension and contact angle as compared to possible pressure variation 
(additional two to three atm may essentially increase ultrasonication efficiency). Therefore,
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higher gas concentration through bubbling agents increases nucleation. An increase in 
pressure will decrease the energy barrier, also resulting in the increase o f bubble nucleation, 
and is thus helpful for the nanoparticle formation. It was found that low wettability of 
materials (which is the case for more hydrophobic low soluble materials) formed the shape of 
a bubble resulting jet flow directing to the particle surface which may increase explosion 
energy [31].
Though the nanoparticulation procedure is reliable, there are number o f features which 
have to be discussed and clarified in future studies:
1) The role o f adsorbed polyelectrolytes may be not only in the particle surface 
re-charging but may also serve as cleaving agents, filling and widening microcracks 
caused by sonication. Dependence o f the procedure on molecular weight o f the used 
polyelectrolytes may be important.
2) In all our experiments, electrical surface potential (^-potential) o f micro/nano particles 
after ultrasonication (but before polyelectrolyte deposition) was negative. It may be due to 
partial oxidation of the particle surface under ultrasonication. This assumption has to be 
checked and control over the depth o f such oxidation may require operations in nitrogen 
atmosphere.
3) Even increasing ultrasonication power and extending its time did not allow smaller 
particle sizes: 2 0 0 -nm diameter was a kind o f “magic” barrier for many o f our colloidal 
particles. We suggested that diameter barrier may be related to the nucleation size o f vapor 
bubbles. This assumption allowed us to decrease colloid particles to 150 nm diameter using 
agents enhancing bubbling formation (such as NH 4 HCO3 ). The process o f the bubble 
nucleation related with materials hydrophobicity has to be analyzed to get even smaller 
particle sizes.
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3.7 Conclusions
Paclitaxel nanoparticles LbL coated by biodegradable (chitosan/alginic acid ) 3  shells were 
produced with the size in the range o f 150-200 nm. Bubbling agents allowed higher 
ultrasonication power for smaller paclitaxel nanocores formation. These nanocolloids were 
stable for at least one week in water at concentrations o f 0.5 mg/ml and pH 6.5. In Chapter 
Four, we will describe another drug nano-core formulation which helped us to avoid titanium 
dioxide contamination.
CHAPTER 4
BO TTO M -U P A PPR O A C H  FO R  DRUG  N A N O FO R M U LA TIO N
There are two approaches applied in our study. One is top-down approach with powerful 
ultrasonication as discussed in the previous chapter. In this approach, we used paclitaxel as a 
representative low soluble drug and obtained good results with LbL encapsulation o f ca 150 
nm diameter nanoparticles. However, a large obstacle o f this method was a necessity o f long 
ca one hour high power ultrasonication which resulted in TiOi nanoparticle detachment from 
the titanium electrode and contamination o f the sample. Mice injection even was possible but 
unsafe for small animals.
The other approach is the bottom-up approach with the surfactants such as lipids, 
Polysorbate 80 (TWEEN 80), or albumin possessing some amphiphilic properties. We 
applied this approach for paclitaxel and lapatinib nanocores formation accomplished with 
LbL encapsulation. In this approach, a low soluble drug was dissolved in a good solvent 
(ethanol) for dissolution into molecular solution and then desolvation process (water addition 
initiating crystallization) with permanent sonication and addition was applied. Amphiphile 
molecules were added to the mixture to arrest drug nucleation and to provide charged sites 
for anchoring o f the fist polycation layer coating. This approach was quite different from the 
top-down approach in the kinetics o f the nanoparticle formation (nanocrystal growth from 
molecular solution) rather than from breaking down bigger crystals. Some sections o f this 
chapter were published in a paper written by the author o f this dissertation in co-authorship 
with Dr. Lvov and others as “Top-down and Bottom-up Approaches in Production of
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Aqueous Nanocolloids o f Low Solubility Drug Paclitaxel”, in Physical Chemistry Chemical 
Physics, 2011,13, 9014-9019. The text sections cited from this paper is properly cited as [73], 
and they are not in use in any other dissertation.
4.1 Bottom-Up Approach with Powerful Ultrasonication
4.1.1 Method Description
Figure 4.1 shows the scheme for bottom-up approach with powerful ultrasonication. In 
this process, a low soluble drug was dissolved in a good solvent (ethanol or acetone). 
Powerful ultrasonication was then applied with amphiphilic Polysorbate 80 and aqueous 
polycations were slowly added into the drug solution. Water was additionally added into the 
solution to decrease the solubility o f the drug in the solution. With the increment o f water 
volume in the drug solution and evaporation o f solvent, solubility o f the chosen drugs 
decreased. The solution would then reach saturation and nucleation would begin to form drug 
nanoparticles. The combination o f powerful ultrasonication and amphiphiles stopped those 
nanoparticles from growing into bigger particles (“arrested” nucleation). As discussed earlier 
in similarity to the top-down approach, oppositely charged polyelectrolytes were then 
sequentially adsorbed onto the surface o f drug nanoparticle to help form a high surface 
charge layer to provide further colloidal stability for drug particles. After 30 minutes o f usual 
sonication treatment (not using very high power but rather usual sonication bath), 
centrifugation at 1 2 , 0 0 0  rotates per minute for 1 0  minutes were applied to precipitate these 
drug crystals already pre-coated with Polysorbate 80 and one polycation layer. They were 
then re-suspended in De-Ionized water. A second layer o f polyelectrolyte (anionic) was 
deposited to further enhance the drug particle surface c,-potential (recharging it to negative). 
Unreacted polyelectrolytes were removed by centrifugation and Layer-by-Layer drug 
nanoparticles with size around 150 nm were obtained both for paclitaxel and lapatinib.
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Further Layer-by-Layer polyelectrolyte was applied for these stabilized nanocolloids for 
building up needed shell architecture using traditional process without powerful 
ultrasonication.
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Figure 4.1 Scheme for bottom-up approach with powerful ultrasonication
Figure 4.2 shows the test result o f temperature o f the solution during ultrasonicaion and 
the evaporation rate o f Di-Ionized (DI) water, 60% Ethanol/De-Ionized water mixture and 
pure ethanol. As we can see, the evaporation rate o f ethanol during powerful ultrasonication 
was close to that o f being heated to 80 °C. Therefore, the temperature in the ultrasonication 
solution was very close to 80 °C. The evaporation rate of De-Ionized water was much smaller 
than ethanol and that o f 60% ethanol/De-Ionized water mixture is in between them. Typically, 
our disolvation process took 25-30 minutes.
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Figure 4.2 Evaporation rate of different solution during sonication
4.1.2 Optimization Process
Here we would like to show our process o f optimization for getting better smaller size 
drug nanoparticles. Our optimization process included the following parameters: solvent type, 
concentration, used amphiphile molecules, water instillation speed, original paclitaxel or 
lapatinib concentration, sonication time and the application o f centrifugation. They are 
discussed in detail below:
1. Solvent ty pe: ethanol VS acetone.
Figure 4.3 shows the effect o f different organic solvent on final drug particle size. 
Paclitaxel (4 mg) in 2 ml ethanol or acetone solvent was sonicated. Then 100 ul 2 mg/ml o f 
poly (allylamine hydrochloride) (PAH) solution was added in, and 2 ml o f De-lonized water 
was slowly added into the solution. As can be seen, the solvent ethanol gives better 
dispersion and less aggregation result for drug nanoparticles than acetone.
55
S-4B00 5£kV 3 S im  *80,0lc SE«U) S-4800 3 QkV 3.8mm *25 «,SE(U)
(a) ethanol (b) acetone
Figure 4.3 SEM image o f final drug nanoparticles by different solvent type
2. Effect of concentration.
Figure 4.4 shows the effect o f solvent concentration (0%, 30%, 60%, 90%) on the final 
nanoparticle size. Paclitaxel (4 mg) in 2 ml ethanol solution (0%, 30%, 60%, 90%) was 
sonicated. Then 100 ul 2mg/ml o f poly (allylamine hydrochloride) (PAP!) solution was added 
in, and 2 ml o f DI water was slowly added into the solution. As we can see, 60% 
ethanol/De-Ionized water mixture gives nest dispersion and particle size.
S-483Q S.OKV 3.emm xSQ.OK 3E(M)S -4 8 0 0  5  0KV 3.6m m  *5Q.0k SE(U) 1.00um
(a) 0 % (b) 30%
56
; S48Q0 S.QKV 3.0mm x120k 5E(U>
(c) 60% (d) 90%
Figure 4.4 SEM image of final drug nanoparticles by different ethanol concentration
3. Water instillation speed.
Figure 4.5 shows the effect o f DI water addition speed on particle size. With the 
increment o f addition speed, particle size grows bigger. This effect can be explained by the 
fact that with the increment o f  addition speed, the solubility decreases faster leading to faster 
crystal nucleation rate and the possibility of aggregation gets higher leading to the increment 
in the final drug particle size. The low DI water addition speed at 0.5 ml/min allowed the 
drug molecule to form crystals slowly and protected and stabilized by polyelectrolytes with 
smallest size.
3 0 0  i
2 5 0
S 200
•  1 5 0
100
5 0
0 .5  1 1 .5  2
W ater addition rate (mi/min)
Figure 4.5 Effect o f DI add in speed on particle size [73]
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4. Drug concentration.
As one can see from Figure 4.6, with the increment in the initial drug concentration, the 
aggregation tendency during nucleation process increased leading the final particle size 
getting larger.
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Figure 4.6 Effect o f drug (paclitaxel) initial concentration on particle size [73]
5. Sonication time.
With the increment o f sonication time (Figure 4.7), the drug particle size decreased. After 
45 minutes, there is no big change in particle size. Therefore, in our study, 45 minutes o f 
ultrasonication w'ere usually applied for the coating o f first polyelectrolyte layer.
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Figure 4.7 Effect o f sonication time on paclitaxel particle size
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6. Centrifugation.
In our approach, we still had some larger particles at the edge o f the container which 
would be harmful. Therefore, centrifugation was been applied for removing bigger particles. 
The result can be seen in Figure 4.8. ■
H ll l jH l ih f i
(a) before centrifugation 
Figure 4.8 Centrifugations to eliminate bigger particles
(b) after centrifugation
Figure 4.9 shows the increment o f centrifuge speed and time decreases the final particle 
size to a certain extent. Our optimization result was choosing 2000 rpm and 10 minutes as the
59
premium speed and time, since too high centrifuge speed and too long at a time will cost the 
loss of drug concentration.
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Figure 4.9 Effect o f (a) centrifuge speed (r/min) and (b) time in minutes (2000 r/min) on the 
paclitaxel particle size (the y-axis, in nanometers)
4.1.3 Bottom-up Method with Bubbling Agent Enhancement
With the optimized process above, we then applied the bubbling agent to the bottom-up 
approach. The procedure for bottom-up method with bubbling agent is described below:
1) Dissolve 0.5 mg/ml o f drug in 20 ml 60% Ethaol/De-Ionized water solution and start 
ultrasonication for five minutes; 2) Add in polycation and bubbling agent solution (1 mg/ml) 
and further apply ultrasonication for 45 minutes; 3) Slowly add in DI water during sonication, 
The solubility o f the drug will decrease and crystallization will be initiated but being kept 
from growing into larger particle with sonication and polyelectrolyte coating; 4) Bottom-up 
method with bubbling agent will produce drugs with 30 nm in size; 5) Polycation coating of 
nanoparticles provides colloidal stability and allow further LbL shell formation.
The result for bottom-up method with bubbling agent enhanced method is shown in 
Figure 4.10. Some very small drug particles with the sized around 30-40 nm in size are 
available.
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Figure 4.10 Bottom-up method with bubbling agent (images from different part o f the 
paclitaxel sample)
4.1.4 Bottom-up Approach with Magnetic Particle Milling
Preparation: 1) 0.5 mg/ml Pac in 20 ml 60% Ethanol/Di water. Sonicate for five minutes.
2) Add in 2/0.5/1 mg/mg/ml PAH/ Fe3 CVDI 3ml drop by drop in three minutes. 3) Add in 
0.5/0.125/1 mg/mg/ml PAH/FesCVDI 20 ml using syringe for 45 minutes. Notes: Fe3 C>4 was 
not completely dissolved in DI. Take upper liquid for experiment. 4) Take the sample after 
sonication, centrifugation, filtration, and centrifugation plus filtration samples, denoted as 1, 
2, 3 and 4 for SEM.
Figure 4.11 shows the SEM image o f bottom-up method with magnetic particles for 
sample 3 after filtration. We can see many 20 nm particles on the edges , which could be
Fe3 C>4 after sonication. Drug particles around 200 nm in size were obtained. For the sample 
after centrifugation and filtration process in Figure 4.12, we still see some drug surrounded 
by Fe3 C>4 , but the concentration may not be high enough. This process can be further studied 
and improved.
(a) edge o f the sample (b) center o f the sample
Figure 4.11 SEM image o f bottom-up method with magnetic particles
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Figure 4.12 SEM sample of magnetic particle coating on the drug after centrifugation and 
filtration process
4.2 Bottom-up with Surfactants Assisted Sonication Approach
Another bottom-up approach applied in our research is using those surfactants such as 
albumin, polysorbate 80 (TWEEN 80) and polyvinylpyrrolidone (PVP) during sonication. 
We applied this approach for paclitaxel and lapatinib. In this approach, we use a regular 
sonicator rather than a powerful ultrasonicator. Since the samples prepared by powerful 
ultrasonicator usually has black precipitate o f TiCT which polluted of the drug nanocapsules. 
It is difficult to remove them because they have close particle sizes. Therefore, we used 
regular sonication and combined our LbL approach with traditional emulsification process 
with addition o f biodegradable surfactants to anchor polyelectrolytes on the surface o f the
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formed drug nanoparticles. This chapter is mostly devoted to our second anticancer drug at 
work: lapatinib. Chapter Six o f this dissertation will show, for the first time, the combined 
action o f these two drugs assembled within one LbL nanocapsule.
Figure 4.13 shows the chemical structure o f lapatinib. It is a drug with very low solubility. 
It is widely used as an orally active drug for breast cancer.
(a) Chemical structure of lapatinib (b) Chemical modeling structure o f lapatinib
Figure 4.13 Lapatinib structural formulas
Let us give a brief introduction o f the surfactants used in this study. The chemical 
structure o f polysorbate 80 (TWEEN 80) and polyvinylpyrrolidone (PVP) are shown in 
Figure 4.14. Polysorbate 80(TWEEN 80) is an emulsifier and nonionic surfactant.lt is a 
viscous and soluble yellow liquid widely used in the food industry. It is derivative ofoleic 
acid and polyethoxylated sorbitan. Its hydrophilic polyethers groups (polyoxyethylene groups) 
are biocompatible. Polyvinylpyrrolidone (PVP) is a water-soluble polymer. It is polymerized 
from its monomer N-vinylpyrrolidone.
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(a) Polysorbate 80 (TWEEN 80)
Figure 4.14 Polysorbate 80 and polyvinylpyrrolidone
n
(b) Polyvinylpyrrolidone (PVP)
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For this approach, a small amount o f albumin and polyvinylpyrrolidone was added into 
PBS (Phosphate buffered saline) buffer solution and then regular sonication was applied. A 
low soluble drug was dissolved in a good solvent (DMSO) for dissolution into molecule and 
then added into the surfactant solution during sonication. Biocompatible polyelectrolyte 
PLB16-5 (PEG and PLL (Polylysine) block copolymer PLL [16kDa]-b-PEG [5kDa] as 
shown in Figure 4.15) was added for LbL coating.
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Figure 4.15 PLL -block-PEG (PLB)
4.3 Conclusions
In this chapter, we described LbL nanoencapsulation of another anticancer drug: lapatinib. 
In Chapter Seven we will demonstrate LbL assembly o f paclitaxel and lapatinib in one LbL 
capsule.
CHAPTER 5
CAPSULE PEGYLATION AND CONTROLLED RELEASE 
STUDY FOR LAPATINIB AND PACLITAXEL
5.1 PEGylation
5.1.1 PEGylation Process
To overcom e difficulties with drug nanoform ulation colloidal stability in high m olarity PBS 
(Phosphate Buffered Saline) buffer, we developed LbL shells with PEG ylation. For this we used 
block copolym er o f  cationic PLL with PEG. N o essential changes in the LbL deposition m ethod 
were necessary. The detailed procedure for PEGylaed shell assem bly is shown below:
1) Two point five microliters o f  PBS, 10 pi 60 mg/ml o f  album in/PBS, 50 pi o f  PVP (80 
mg/m l) added together and sonicate for two m inutes.
2) During sonication, add 200 pi lapatinib/D M SO (7 mg/ml), keep sonication for 20 m inutes.
3) Using around 20 pi PLB (PEG and polylysine block copolym er) (60 mg/ml in acidic 
PBS), 20 pi heparin (60 mg/ml in acidic PBS) for layer by layer coating by sonicating for one 
minute each time.
4) Taking half m ililiter sample, centrifuge at 2,000 rpm for 10 m inutes, and keep the 
supernatant, we get nanoparticles 150 nm in size.
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5) Centrifuging the above supernatant at 10,000 rpm for 1 0  minutes, get the bottom 
sample, sonicate and add in the same amount o f PBS, and get particle size at 125 nm as 
shown in Figure 5.1.
09  
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0.3 
0.1
Figure 5.1 Lapatinib particle size after PEGylation (X-axis: size in nm, Y-axis: ratio of 
particles o f certain size as compared to the total particles)
6 ) The steps three to five were repeated to make 3.5 bilayers on top o f the drug particles 
with heparin being the outmost layer. Drug particles around 180 nm in size, -36 pv in surface 
charge were obtained. Figure 5.2 shows the SEM image for lapatinib nanoparticles with 3.5 
bilayers o f PLB (polyethylene glycol and polylysine block copolymer) and heparin.
95% R=125nm
Figure 5.2 SEM image for lapatinib nanoparticles after Layer-by-Layer coating; the shell 
composition is as follows: lapatinib/albumin/ (PLB 16-5/heparin) 3 5
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5.1.2 Monitoring of the Assembly Process with PEGvlation
The relationship between zeta potential and the amount o f  polyelectrolyte (PE) volume 
has been shown in Figure 5.3. The initial zeta potential for drug particle without any 
PLB16-5 (PEG and PLL (Polylysine) block copolymer PLL [16kDa]-b-PEG [5kDa]) coating 
is around -36 ± 2 mV with albumin coating as the outer layer. With the addition o f PLB 
(Polyethylene glycol (PEG) solution, the zeta potential increased gradually to around 
38 ± 2 mV, and with the addition o f negative polyelectrolyte heparin, the zeta potential 
decreased gradually to around -39 ± 2 mV. The amount of heparin used was a little bit larger 
than that o f PLB (Polyethylene glycol (PEG) solution. This process can be repeated as shown 
in Figure 5.3. This method allowed researchers to avoid the intermediate sample 
centrifugation because due to step-wise polycation/polyanion addition, we were able to find 
the point of complete particle recharging and switched to the oppositely charged 
polyelectrolyte.
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Figure 5.3 Zeta potential (y-axis, unit: mV) VS Polyelectrolyte (PE) volume (X-axis, unit: ul). 
Zeta potential monitoring o f lapatinib drug during coating, at each point at the graph we 
added 0.02 mL polyelectrolytes (first cationic, then anionic, and further again cationic and 
anionic, following the particle recharging process), the shell composition is as follows: 
lapatinib/albumin/ (PLB 16-5/heparin)2
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5.2 Controlled Release Study
5.2.1 Concentration Study and Productivity o f Our Method
In our study, we want to figure the productivity o f our drug o f the Layer-by-Layer coating. 
The most common method for detection the concentration is to use UV spectroscopy for the 
calibration and testament o f  the concentration o f the drug. The calibration curve for lapatinib 
in DMSO is shown in Figure 5.4. The result was applied for the study o f concentration of 
lapatinib in the solution.
y = 52.483x + 0.0966  
R2 = 0.9999 ^
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Figure 5.4 UV calibration result for lapatinib in DMSO (concentration mg/ml)
The initial lapatinib nanoparticle concentration is 0.45 mg/ml. After the Layer-by-Layer 
coating, final centrifugation at 12000 rpm for 10 minutes, and remove the upper liquid, 
re-disperse in same amount o f PBS, the nanoparticle concentration is 0.25 mg/ml, which is 
around 56% of productivity.
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5.2.2 Release Test for Lapatinib in PBS Buffer
Lapatinib release study in 80 mg/ml PBS-TW80:
Add 0.05 ml nano-lapatinib into 2 ml 80 mg/ml PBS TW80, test its UV absorbance. It is 
used as the total concentration for release in UV test.
Add 0.05 ml nano-lapatinib into 150 ml PBS-TW80 for release test. Each time take 2 ml 
for UV tests.
Draw the release curve according to the Absorbance data as shown in Figure 5.5.
The release time for 97.4% release is, therefore, four hours, and the release equation is a 
log equation: y=0.27351n(x)-0.512. And the confidence o f this release curve is R2=0.9264.
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Figure 5.5 Lapatinib nanocapsule release study in 80 mg/ml PBS-TW80
5.2.3 Release o f Drug from Different Formulation (Effect o f LbL Shell)
This section was published in a paper written by the author o f this dissertation in 
co-authorship with Dr. Lvov and others as “Top-down and Bottom-up Approaches in 
Production o f Aqueous Nanocolloids o f Low Solublility Drug Paclitaxel,” in Physical
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Chemistry Chemical Physics, 2011, 13, 9014-9019. The text section cited from this paper is 
properly cited as [73], and they are not in use in any other dissertation.
The release profiles o f original paclitaxel powder, paclitaxel nanocolloids with one 
polycation layer and three polycation/polyanion bilayer coating were analyzed in standard 
sink conditions (initial drug concentration was 2 mg/ml). The release curves fitting were done 
with exponential Peppas’ model. Seventy percent o f original paclitaxel powder was released 
within eight hours (Figure 5.6).
100  -
80
2 40
♦  Nano paclitaxel 
original paclitaxel 
▲ paclitaxel-(PAH/BSA)210
Figure 5.6 Release from paclitaxel nanocolloidal particles produced with SLbL top-down 
approach: PAH coating-1, original paclitaxel without coating-2, and (PAH/BSA)3 coating-3 
[73].
Nanoparticulated paclitaxel coated with one polyelectrolyte layer lead to slightly faster 
release due to smaller particle size in nanoformulation as compared with micrometer size o f 
the original paclitaxel. Paclitaxel nanocolloids coated with three bilayers o f PAH / BSA 
showed lower drug release rate due to increasing thickness o f  the capsule wall. For example, 
in eight hours only 40% o f the two layers coated sample was released as compared with 80% 
for one layer coated sample. LbL technique allows for control of drug release rate from
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polyelectrolytes-stabilized nanoparticles by changes the number o f coating layers or the shell 
composition.
Under sink conditions, 50% of non-coated paclitaxel crystals (without sonication) were 
solubilized within two hours, while three LbL coating bilayers extended this time to more 
than ten hours (extrapolation). Similar release rate results were obtained for bottom-up 
approach in paclitaxel nanoparticulation. Paclitaxel coated with one layer o f PAH after 
bottom-up approach (particle size was 100 ± 20 nm) showed slightly faster release than 
top-down approach (particle size is 220 ± 20 nm) due to the smaller particle size.
Conclusions: In the proposed paclitaxel and lapatinib formulation, we obtained 
150-200 nm drug particles, but our nanocapsules contained high drug content o f 80-90% due 
to very thin capsule walls (of ca 10 nm, as it was estimated from Quartz Crystal 
Microbalance measurements o f the LbL multilayers o f  corresponding compositions). The 
drug release time from LbL capsules was found to be between 10 and 20 hours depending on 
the shell thickness.
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C H A PT E R  6
D U A L D RUG S EN C A PSU LA TIO N  OF  
PACLITAXEL A N D  LAPATINIB
In this chapter, the preparation and characterization o f dual drug paclitaxel and lapatinib 
is shown. In a multidrug-resistant (MDR) ovarian cancer cell line, OVCAR-3, 
paclitaxel/lapatinib nanocolloids mediated an enhanced cell growth inhibition in comparison 
with the paclitaxel-only treatment. A series o f  in vitro cell assays were used to test the 
efficacy o f these formulations. The small size and functional versatility o f these nanoparticles, 
combined with their ability to incorporate various drugs, indicated that paclitaxel/lapatinib 
nanocolloids may have in vivo therapeutic applications. Some sections o f this chapter were 
published in a paper written by the author o f  this dissertation as “ Lapatinib/Paclitaxel 
Polyelectrolyte Nanocapsules for Overcoming Multidrug Resistance in Ovarian Cancer,” in 
Nanomedicine: Nanotechnology, Biology, and Medicine (2011 Nov 16) [74].
Figure 6.1 shows how the drug particles are formulated (basically based on the former 
sonication assisted Layer-by-Layer approach) and the in vivo toxicity test o f 
paclitaxel/lapatinib colloidal nanoparticles. It will be discussed in detail in the following 
sections o f this chapter.
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I. Fnrniation ot colloidal n .tin ■ par licit--
II. In  Miro Invicitv of Pacliiavcl ' I.apatinih co.lnidal na i inparlick '
Figure 6.1 Formulation and in vivo toxicity test o f paclitaxel/lapatinib colloidal nanoparticles 
[74] (The bottom left picture: red dots: lapatinib. black dots: paclitaxel. The bottom right 
picture is shown in Figure 6.9)
6.1 Introduction
Ovarian cancer is one o f the most common gynaecological malignancies in women and 
the leading cause o f gynaecological cancer-related deaths in dev eloping countries [76]. This 
mortality rate is due to the lack o f early symptoms for ovarian cancer that becomes clinically 
evident until it reaches an advanced stage. The picture is complicated by the failure o f the 
current available therapies that are not very effective. The major obstacle is the presence o f 
several mechanisms o f drug resistance, some of which have been well described, for many o f 
the currently chemotherapies used for the treatment o f ovarian cancer including paclitaxel 
[77]. Paclitaxel is a drug o f natural origin isolated from the bark of Taxusbrevifolia [78] and 
currently used for the treatment o f ovarian cancer and breast cancer. Paclitaxel promotes 
microtubule assembly and stability, an effect that results in the disruption o f  the normal 
microtubule network required for mitosis.
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Efforts have been made over the past years to overcome drug resistance associated with 
paclitaxel treatment and a number o f specific factors have been identified as causes of 
paclitaxel resistance; however, the underlying complex mechanisms are far from fully 
understood. Paclitaxel resistance has been associated with the overexpression of 
P-glycoprotein, altered expression o f specific tubulin isotypes, activation o f the Toll-like 
receptor (TLR)-MyD88 signaling pathway and H IF-lalpha stimulation by hypoxia [79-83], 
Furthermore, paclitaxel presents a poor solubility in water and it is formulated for its 
current clinical administration in a mixture o f Cremophor EL/absolute ethanol (50% v/v). 
This preparation has been associated with several side effects including nephrotoxicity and 
neurotoxicity [84].
To overcome toxicity, to increase bioavailability and to control drug release, several 
approaches for packing paclitaxel are under investigation. Since 2005, albumin-based 
nanoparticles were approved by the US Food and Drug Administration and, during these 
years, new nanoparticle formulations, such as polymeric nanoparticles, micelles, dendrimers 
and liposomes, demonstrated to possess numerous benefits over conventional methods and 
early nanoparticles products [85-88],
Among the wide panel of novel formulations under investigation, previous studies have 
shown that Layer-by-Layer nanoassembly technique can be used efficiently for the 
nano-encapsulation o f poorly soluble anti-cancer drugs [72].
In particular, stable nanocolloids o f paclitaxel were prepared by sonication assisted 
Layer-by-Layer (SLbL) self assembly technology. Under powerful ultrasonication, the 
air-bubble dissolved in water underwent the formation and implosion o f cavity, followed by 
the jet flow and thus extreme physico-chemical environment was created. Drug crystals were 
broken into smaller and smaller particles. During this process, polyelectrolyte o f opposite 
charge to the drug was added and absorbed onto the drug crystals through electrostatic forces:
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this helps for preventing aggregation of the newly formed nanoparticles. Since the 
ultrasonication is based on the collapse o f air-bubbles, a bubbling agent such as N H 4 H C O 3 
was mixed with the polyelectrolyte to increase the intensity o f  ultrasonication [72], By this 
method, drug nanoparticles around 150 ± 50 nm in size were achieved. Generally speaking, 
initial drug particles are negative in charge. After the first polyelectrolyte coating (in this case, 
polycation), the surface potential becomes positive. Then a second layer polyelectrolyte (in 
this case, polyanion), was coated and the surface charge reversed back to negative. This 
surface charge reversal can be repeated several times to demonstrate the successful coating of 
different polyelectrolyte layers which can build up such architecture and maintain properties 
such as controlled release by tailoring layers composition and number. The Layer-by-Layer 
self assembly technology can also be applied for combining two drugs in one nanocolloid 
system for enhancing synergistically drug efficiency [73].
For all these reasons, we hypothesized that paclitaxel clinical efficacy can be increased 
through a strategy that combines improvements in paclitaxel cellular delivery and 
combination o f targeted therapies to inhibit one or more signalling pathways involved in 
paclitaxel resistance. O f all these mechanisms o f drug resistance, overexpression of 
P-glycoprotein (P-gp), a member o f the ATP-binding cassette (ABC) transporters [89], has 
been associated with a poor response to chemotherapy [90]; therefore, its impairment is likely 
to have a significant impact on paclitaxel clinical action. However, until now, many P-gp 
inhibitors failed during pre-clinical and clinical studies [91]. Recently, lapatinib, an epidermal 
growth factor receptor (EGFR) and Erb-2 dual tyrosine kinase inhibitor have been shown to 
inhibit the function o f ABC transporters including P-gp [92],
In this work, the efficacy o f paclitaxel-Ioaded nanocolloid formulations has been tested 
in two ovarian cancer cell lines in vitro compared to that o f paclitaxel given alone.
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Furthermore, a co-therapv strategy which results from the combination o f paclitaxel and 
lapatinib in nanocolloids showed to be very effective in enhancing paclitaxel efficacy.
Overall, results o f this study showed that paclitaxel-nanocolloids increased antitumor 
efficacy o f paclitaxel and that the combination with lapatinib, can significantly overcome 
multidrug resistance in ovarian cancer cell lines. These results are encouraging for the 
development o f multifunctional nanocolloids that could be used in the clinical practice.
6.2 Methods
6.2.1 P reparation  o f  N anocollo ids
To build up the nanocapsules for a simultaneous controlled release o f two drugs, we used 
a SLBL technique. Biodegradable chitosan (polycation) and alginic acid (polyanion) were 
chosen for a biocompatible and biodegradable coating on drug NPs.
A Heilscher UIP lOOOhd Ultrasonicator (Germany) was applied at its maximum power 
(15 WcnT2) to break the drug colloid into smaller nanoparticles. Water/ ice mixture was used 
for the cooling o f the beaker with drug particles under the powerful ultraasonicatior to 
prevent overheating and oxidation o f the drug.
1) Paclitaxel samples.
Paclitaxel (40 mg), chitosan (6 mg) (MW=2500) and N H 4 H C O 3 (40 mg) were added to 
30 ml De-Ionized (DI) water, stirred for Five minutes and then sonicated in water/ice bath for 
45 minutes (to make paclitaxel/chitosan). After 45 minutes, six ml alginic acid solution (one 
mg/ml) was added in during sonication; sonicated for 25 minutes (to make paclitaxel 
/chitosan/ alginic acid).
The coating process o f chitosan and alginic acid were repeated to make 
(paclitaxel/chitosan/alginic acid/chitosan/alginic acid /chitosan/alginic acid) nanocolloid.
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2) Paclitaxel/lapatinib dual drug nanocolloids preparation: (paclitaxel/chitosan/alginic 
acid/chitosan/lapatinib/chitosan/alginic acid).
Paclitaxel (40 mg), chitosan (6 mg) and N H 4 H C O 3 (40 mg) were added in 30 ml 
De-lonized (Dl) water, stirred for five minutes and then sonicated in water/ice bath for 45 
minutes (to make paclitaxel/chitosan complex). After 45 minutes, 6 ml alginic acid solution 
(1 mg/ml) was added during sonication for 25 minutes (to make paclitaxel/chitosan/alginic 
acid). Six milliliter o f 1 mg/ml chitosan solution was added, and then sonicated for 25 
minutes (to make paclitaxel/chitosan/alginic acid/chitosan). Lapatinib solution (20 ml, 0.5 
mg/ml) was added for sonication for 25 minutes (to make paclitaxel/chitosan/alginic 
acid/chitosan/lapatinib). Chitosan (6 ml, 1 mg/ml) solution was added under sonication for 25 
minutes (to produce paclitaxel/chitosan/alginic acid/chitosan/lapatinib/chitosan). Six 
milliliter o f AA solution (in 1 mg/ml concentration) was added, and then sonicated for 25 
minutes (to make paclitaxel/chitosan/alginic acid/chitosan/lapatinib/chitosan/alginic acid). 
Samples were centrifuged at 2000 rpm for 20 minutes to remove lower solid. The samples 
were then centrifuged at 10000 rpm for 10 minutes to remove upper liquid.
6.2.2 Cell V iability A ssay
Cells were seeded at a density o f 5 x 103 per well in a 96-well plate containing 100 pi o f 
full medium and allowed to adhere to the plate overnight. For determining cell viability, the 
MTT assay was used. After treatment with paclitaxel or LbL-paclitaxel nanocolloids for 
24 hours, the culture medium was aspirated and 100 pi o f fresh medium containing 10 pi o f 
MTT solution (stock five mg/ml in PBS) was added to each well. Cells were then incubated 
for further two to three hours. After removal o f MTT solution, 100 pi o f DMSO were added 
to the wells maintained in agitation for 15 minutes. Absorbance of the converted dye was 
measured at a wavelength of 570 nm with background subtraction at 690 nm. The relative 
cell viability was expressed as a percentage o f the untreated control wells.
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6.2.3 R everse Transcription-PC R
Total cellular RNA was isolated by IllustratriplePrep extraction kit following 
manufacter’s instruction and immediately used. Purified DNA and protein pellets were stored 
at -80° C for further analysis.
Reverse transcription polymerase chain reaction was then performed by using the High 
Capacity RNA-to-cDNA Master Mix (Applied Biosystem). Approximately one pg o f total 
RNA was converted to cDNA.
PCR was conducted on a MyCycIer thermal cycler (Bio-Rad). The final volume o f 25 pi 
included one pi o f cDNA template, 12.5 pi o f PCR Master Mix (Promega), and one pi o f a 
mix containing primers.
The primers used for PCR amplification were designed using the Primer blast program 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and were as follows: Cofilin sense 5’ 
GTGGGCGATGTGGGCCAGAC 3 ’, antisense 5’ CCAGGGTGCAGCGGTCCTTG 3 ’ (280 
base pairs, bp, Tm 60°); Cyclin D1 sense 5’ CGCTTCCTGTCGCTGGAGCC 3’, antisense 5 ’ 
CTTCTCGGCCGTCAGGGGA 3’ (111 bp, Tm 60°); GAPDH sense 5 ’
GCATGGCCTTCCGTGTCCCC 3’, antisense 5’ CAATGCCAGCCCCAGCGTCA 3 ’ (216 
bp, Tm 60°).
PCR was carried out using the following conditions: denaturation at 95 °C for 30 s, 
annealing at 60 °C for 30 s, and extension at 72 °C for 45 s. PCR samples were loaded onto a
1.2 % agarose gel containing ethidium bromide and analysed. All PCR experiments were run 
in triplicate. GAPDH was used as an internal loading control.
6 .2.4 Im m unoblotting  Assay
Proteins were extracted in RIPA buffer (50 mM Tris-base, 150 mM NaCl, 0.1% SDS, 1% 
Triton X-100, 0.5% sodium deoxycholate, one mM sodium orthovanadate, 10 mM sodium 
fluoride, 1% protease inhibitor cocktail) and lysates were clarified by centrifugation at
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13000 g for 15 minutes at 4°C. Protein concentration was determined using the Bradford 
protein assay. Proteins (50 pg) were separated on 10% polyacrylammide gel and transferred 
to nitrocellulose membranes (Amersham Biosciences). The membranes were blocked 
overnight in 5% non-fat milk in TBST buffer (Tris Buffer Saline and 0.1 % Tween 20) at 4°C 
under agitation, and subsequently probed by the appropriately diluted primary antibodies in 
blocking buffer. The blots were then incubated with HRP-conjugated secondare antibody for 
two hours at room temperature. Target proteins were detected by enhanced 
chemiluminescence reagents and visualized on Hyperfilm ECL films (Amersham).
6.2.5 Confocal M icroscopy
Exponentially growing ovarian cancer cells were seeded on 25 mm square glass cover 
slips placed in 35 mm diameter culture dishes. After treatment, cells were fixed for five 
minutes with 3.7% formaldehyde in phosphate-buffered saline (PBS) solution, permeabilized 
with a 0.1% solution o f Triton X-100 in PBS, and incubated for 30 minutes at room 
temperature with phalloidin-TRITC (Sigma) (one pgfnl in PBS from one m gfnl DMSO stock 
solution). After that, cells were washed three times in PBS. The preparations were mounted 
in 50% glycerol in PBS. Images were acquired by laser confocal microscopy using a TCS 
SP5 (Leica Microsystem GmbH, Mannheim, Germany).
6.2.6 Statistical A nalysis
Statistical analysis was performed using GraphPad Prism 4.1 (GraphPad Software, San 
Diego, CA, USA). Differences between group means were compared by Student's t-test. 
Student’s t-test was used for the statistical analysis o f RT-PCR and western blot data. Data 
are presented as mean ± standard error o f the mean (s.e.m.). A probability level o f P < 0.05 
was considered significant.
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6.3 Results
The aim o f this study is to develop new strategies based on nanocolloids technology to 
overcome multiple drug resistance (MDR) associated with paclitaxel in ovarian cancer. 
Preliminary experiments were performed to identify cellular targets o f paclitaxel action. The 
identification o f these targets will be useful as markers o f nanocolloids action respect to 
paclitaxel alone.
An ovarian cancer cell line, OVCAR-3, was chosen for its drug-resistance phenotype and 
used as model system in this study. The MDR phenotype o f this cell line was confirmed by 
the presence at mRNA level o f TLR4 and P-glycoprotein (P-gp) (Figure 6.2 E), which were 
associated with paclitaxel chemoresistance [79, 81-82]. The expression levels o f these 
mRNA. MDR1 mRNA is greatly expressed in OVCAR-3 with respect to MCF-7 while no 
significant differences were observed for TLR-4.
The over-expression o f the glycoprotein P-gp, a member of the ATP-binding cassette 
(ABC) protein family, has profound implications in the clinical practice. In fact, the presence 
o f drug efflux pumps that mediate the active efflux o f  chemotheraputics is one o f the most 
extensively described mechanisms of drug resistance and strategies to modulate or blocking 
this process that have been investigated actively in oncology [93], In ovarian cancer, P-gp 
overexpression at the mRNA and protein level has been implicated in chemoresistance, 
correlated inversely with patient survival and associated with resistance to paclitaxel [94-96],
Dose-response studies highlighted the resistant nature o f this cell line (Figure 6.2 B). 
Exponentially growing OVCAR-3 cells were exposed to increasing concentration o f 
paclitaxel (from 1.5 ng/ ml to 5000 ng/ ml) for 24 hours and MTT cell viability assay was 
performed. As shown in Figure 6.2, the cancer cell line exhibited a characteristic 
dose-response curve, in fact, treatment with paclitaxel at concentration above 10 ng/ml did 
not induce a proportional reduction of cell viability.
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Figure 6.2 Paclitaxel inhibits cell growth o f OVCAR-3 cells
A) Evaluation o f the effects o f paclitaxel on OVCAR-3 cell morphology using phase-contrast 
microscopy after 24 hours o f incubation (magnification 10 x). Cell death was observed 
after paclitaxel treatment as evidenced by the increasing number o f floating cells. B) 
Paclitaxel reduces cell viability. OVCAR-3 were seeded overnight into 24-well plates and 
incubated with paclitaxel at the indicated concentrations. After 24 hours, cell viability was 
detected by MTT test. OVCAR-3 demonstrated a plateau in survival at concentrations o f 
paclitaxel above 5 ng/ml. Values are mean +/- s.e.m. o f three independent experiments 
performed in triplicate. C) Paclitaxel reduces cell viability. OVCAR-3 were seeded overnight 
into 24-well plates at the indicated concentrations and incubated with paclitaxel for 24 hours 
at 5 pg/ml. The response of OVCAR-3 to paclitaxel is independent o f the number o f cell 
seeded. Values are mean +/- s.e.m. o f three independent experiments performed in triplicate.
D) Paclitaxel reduces Akt phosphorylation at ser 473. OVCAR-3 cells were cultered in 
DMEM media supplemented with 10% FBS for 24 hours followed by starvation for 12 hours 
in serum-free media. Cells were switched to the media in the absence (CTR) or presence 
(treated) o f paclitaxel 5 pg/ ml for 15 minutes, 1 hour, 4 hours and 24 hours, respectively. 
The whole cell lysates were prepared, and western blotting was performed as described in the 
Materials and Methods. Blots were stripped and re-probed with total Akt isoforms. The level 
o f tubulin was used to indicate relative amounts o f  protein loaded. Experiments were 
performed three times and blot is a representative o f one independent experiment. (Right) 
paclitaxel effects on the expression o f Akt 1, Akt 2. RT-PCR showed mRNA levels o f Akt 
isoforms after paclitaxel treatment. The expression o f GAPDH is shown as internal control.
E) Expression o f MDR1 and TLR4 measured by RT-PCR in untreated OVCAR-3 and MCF-7 
cells. The expression o f GAPDH is shown as internal control.
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Comparable findings were obtained in a similar experiment, in which the drug 
concentration was maintained fixed and the number o f cell seeded on the plate was changed 
(Figure 6.2 C). Ovarian cancer cells seeded at four different concentrations and treated with 
paclitaxel at 5 ng/ ml for 24 hours showed a similar survival ratio between control and treated 
cells. This result means that cytotoxicity due to paclitaxel in less dependent on the 
concentration o f the drug at concentrations above 10 ng/ml. In the case o f OVCAR-3, the 
1C50 could not be determined because even at concentrations of paclitaxel upper than 20 
ng/ml more than 50% o f the cells remained viable (data not shown). In contrast, an IC50 o f 
100-200 ng/ml has been determined by MTT (data not shown) for MCF-7 (drug sensitive) 
cells suggesting that the multidrug resistance transporter MDR-1 is associated with resistance 
to paclitaxel in OVCAR-3.
In recent years, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway has risen to 
prominence as a regulator o f cell survival and growth in many different cell types. In ovarian 
cancer, constitutive Akt activity or gene amplification was frequently detected in tumor 
samples and associated with chemoresistance and poor prognosis [97, 98]. Akt promotes cell 
survival and growth through a variety o f mechanisms, including the regulation of 
proapoptotic proteins Bad and caspase-9 and cyclin D1 expression [97],
To determine the effects o f paclitaxel on this signaling pathway, an experiment of 
western blot was conducted to investigate the phosphorylation status o f Akt ser 473 after 
paclitaxel treatment. Ovarian cancer cell lines were grown under normal conditions and were 
deprived o f serum overnight. Cells were then treated or not (control) with paclitaxel in 
presence o f serum. Western blot analysis showed that levels o f  pAkt ser 473 were reduced 
compared to those in control cells that, on the contrary, increase when stimulated with serum 
at the indicated times (Figure 6.2 D).
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No differences were noted in the levels o f total Akt 1 and Akt 2 isoforms at both mRNA 
and protein levels, suggesting that paclitaxel-regulation of this pathway results largely from 
post-transcriptional regulation.
To investigate whether the encapsulation o f  paclitaxel in nanocolloids leads to a general 
improvement o f  the efficacy o f the drug, we assayed the cytotoxicity o f the LbL-paclitaxel 
toward the OVCAR-3 cell line and compared the results with that of paclitaxel free.
To assess this point, two types o f LbL-nanocolloids were fabricated and tested: 
paclitaxel-chitosan and paclitaxel-chitosan-alginic acid. In particular, chitosan is a positively 
charged natural carbohydrate polymer with minimal toxicity that shows strong electrostatic 
interaction with the negatively charged mucosal surface [98], Chitosan has been largely used 
as biomaterials and the much higher expression o f mucin, heavily glycosylated extracellular 
protein, in ovarian tumors compared to the surrounding normal tissue [99] can provide a 
rationale for using chitosan as delivery system in ovarian tumors. Both preparations were 
tested on ovarian cancer cells for their ability to increase paclitaxel efficacy. The results 
obtained by MTT test were comparable for the two types of nanocolloids, and for this reason, 
we will use the general name of LbL-paclitaxel nanocolloids to design both formulations. As 
shown in Figure 6.3, paclitaxel and LbL-paclitaxel have a similar trend o f cytotoxicity in 
ovarian cells with a higher cytotoxicity for LbL-paclitaxel than paclitaxel alone. It should be 
noted that, since cells incubated for 24 hours with empty LbL-nanocolloids (drug free) does 
not shown any significant difference in cell viability compared to control cells. We exclude a 
role of empty nanocolloids to explain the difference between paclitaxel and LbL-paclitaxel.
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Figure 6.3 Citotoxic effect o f LbL-paclitaxel nanocolloids on OVCAR-3 and SKOV-3 cancer 
cells and regulation o f pAkt ser 473 and cyclin D1 expression
Citotoxic effect o f paclitaxel alone or LbL-paclitaxel nanocolloids at the indicated 
concentrations was measured by the MTT assay as described in Section 6.2. Control cells 
were treated with paclitaxel free or paclitaxel-LbL nanocolloids. Values are mean +/- s.e.m. 
o f three independent experiments performed in triplicate. The cell viability is related to 
control wells treated with vehicle (DMSO) or empty LbL-nanocolloids (drug free).
Regulation o f pAkt ser 473 and cyclin D1 by paclitaxel or LbL-paclitaxel nanocolloids: 
Ovarian cancer cells were treated with paclitaxel or LbL-paclitaxel nanocolloids at the 
concentration o f 1.5 ng/ml for 24 hours. Whole cell lysates (50 pg in each lane) were 
subsequently subjected to western blotting analysis with antibodies to pAkt ser 473 and 
cyclin D l. RT-PCR analysis o f cyclin D1 mRNA expression levels was performed as 
described in Section 6.2.
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Moreover, we observed that the treatment o f ovarian cancer cells with LbL-paclitaxel 
results in cell growth inhibition at the concentration o f  1.5 ng/ml where the same 
concentration o f paclitaxel free does not affect cell viability.
Comparison of ovarian cancer cells treated with LbL-paclitaxel and paclitaxel at the 
concentration o f 1.5 ng/ml revealed a down-regulation o f pAkt ser 473 only for LbL- 
paclitaxel treated cells. Akt pathway is known to play a pivotal role in the regulation o f cyclin 
D1 expression in ovarian cancer cells [100], Therefore, we examined if paclitaxel or 
LbL-paclitaxel nanocolloids regulate cyclin D1 expression. After 24 hours o f  treatment at the 
concentration o f 1.5 ng/ ml only LbL-paclitaxel nanocolloids were able to decrease cyclin D1 
protein level. Cyclin D1 mRNA level remains unaffected after treatment suggesting the 
regulation at the protein level.
We next determined if increased LbL-paclitaxel nanocolloids cytotoxicity respect to 
paclitaxel free could be explained by a higher down-regulation o f the Akt pathway. Western 
blot analysis o f pAkt ser 473 from ovarian cells treated with paclitaxel and LbL-paclitaxel 
nanocolloids at five pg/ml showed a significant difference in the pospho-protein level in 
control with respect to treated cells with a further down-regulation in LbL-paclitaxel treated 
samples (Figure 6.3 B), a finding that correlates with the increased cytotoxicity of 
nanocolloids compared to paclitaxel free.
The enhanced cytotoxicity o f  drug-nanoparticles could be explained considering the 
different mechanisms o f drug-nanocolloids uptake compared to paclitaxel free. Several 
mechanisms have been described including the increased accumulation o f the nanoparticles 
in the cells and their entrapment in the endosomes/lysosomes rendering the drug inaccessible 
for P-gp [101].
A possible link between the activation o f PI3K/Akt pathway and actin remodeling has 
been described [102-103]. It has been shown that PI3K/Akt pathway induced cell migration
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through the remodeling o f actin filaments and that actin is a cellular target o f this kinase 
[104-105]. It is possible that the involvement o f this pathway in paclitaxel action could have 
consequences on the organization o f actin cytoskeleton after paclitaxel treatment. 
TRITC-phalloidin staining of F-actin followed by confocal microscopy analysis revealed 
some differences in the cell shape and organization o f  actin filaments for paclitaxel free and 
LbL-paclitaxel cells compared to control (Figure 6.4 A). Not treated cells show regular 
shaped bodies, with a readily visible actin staining in the periphery, actin profusions (yellow 
arrows. Figure 6.4 A) and the absence o f bundles o f actin filaments. Rounded cells appeared 
after paclitaxel treatment together with the formation of blebs (green arrows. Figure 6.4 A). 
No actin profusions are more v isible in treated cells. Furthermore, a more distinct net o f actin 
filaments is visible in the cytoplasm o f OVCAR-3 treated with LbL-paclitaxel nanocolloids.
pC O F ser 3 
C O P
C O F m R N A
Figure 6.4 Effects o f paclitaxel or LbL-paclitaxel nanocolloids on actin cytoskeleton: 
(A) Ovarian cancer cells plated on glass coverslips were treated with paclitaxel or 
LbL-paclitaxel nanocolloids at the concentration o f 5 pg/ ml for 24 hours and then fixed. 
Cells were stained with TRITC-phalloidin. (B) The phosphorylation status o f cofilin at ser 3 
was assessed with a phoshospecifie antibody, and then the blot was reprobed for total cofilin 
levels. The mRNA level o f cofilin was assessed by using a specific set o f primer.
I he organization o f actin filaments is gov erned by a plethora of proteins that regulate the 
rate o f actin polymerization. One o f the key proteins in this scenario is cofilin. which can 
regulate the rate o f actin-filament turnover and the net polymerization o f actin. In particular.
PTX treated
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actin dynamics is regulated by phosphorylation o f  cofilin at serine, which renders 
phospho-cofilin inactive towards F-actin [106], We examined by western blot the 
phosphorylation status o f cofilin after paclitaxel or LbL-paclitaxel nanocolloids treatment. As 
shown in Figure 6.4 B, cofilin phosphorylation increased after paclitaxel treatment and, in 
particular, after the exposure with LbL-paclitaxel. This result is consistent with the 
morphological actin-changes observed by confocal microscopy and raises questions about the 
role o f the actin cytoskeleton in mediating paclitaxel sensitivity. Moreover, the significant 
effect o f LbL-nanoparticles on cofilin phosphorylation will prompt us to investigate the role 
o f actin cytoskeleton in mediating the uptake the LbL-nanoparticles into OVCAR-3 cells.
In summary, the Akt pathway is a target of paclitaxel and LbL-paclitaxel action; the 
modulation of this pathway after paclitaxel treatment can affect the cell growth as observed 
by MTT.
Moreover, LbL-paclitaxel nanocolloids lower the mininum dose necessary to obtain a 
significative reduction o f cell viability an issue that can be important for future possible 
application in vivo in order to minimize the cytotoxicity and adverse side effects associated 
with paclitaxel. On the other hand, although the cell growth inhibition o f paclitaxel free and 
LbL-paclitaxel nanocolloids reached a statistical difference, nanocolloids did not produce a 
sustained growth inhibition in ovarian cancer cells suggesting that LbL-paclitaxel 
nanocolloids are susceptible to efflux by P-gp. Thus, the combination with an interrelated 
drug is required to optimize the therapeutic activity o f  nanoparticle-encapsulated drug.
In search for novel strategies to overcome resistance of ovarian tumor cells, we tested the 
cytotoxic activity o f paclitaxel in combination with two small molecule chemical inhibitors, 
U0126, an extracellular signal-regulated kinase (ERK) 1/2 inhibitor, and LY29004, a PI3K 
inhibitor. Both signal-pathways have been described and well characterized for their role in 
drug-resistance [97, 107],
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In addition, the combination with lapatinib, an inhibitor o f the intracellular tyrosine 
kinase domains o f both the EGFR and Her-2 receptors, was further explored to increase the 
cytotoxic efficacy o f paclitaxel. The combination o f  lapatinib with paclitaxel has been 
explored in the clinical practice. In fact, clinical trials demonstrated the efficacy o f  lapatinib 
and paclitaxel in HER-2-positive locally advanced or metastatic breast cancer [103], 
Moreover, the ability o f lapatinib to reverse multidrug resistance due to ABCB1 and ABCG2 
transporters, including P-gp, has been recently described with the potential to increase the 
cytotoxic effects o f several chemotherapeutic drugs including paclitaxel [108]. This finding 
supports the idea to combine paclitaxel and lapatinib in our cell line that shows a high 
expression o f P-gp. As shown in Figure 6.5, an improvement of paclitaxel efficacy is 
obtained when the drug is administrated in combination with the ERK 1/2 inhibitor U0126, 
suggesting that this pathway may play a role in the generation o f paclitaxel resistance, and a 
greatly enhanced of paclitaxel efficacy is obtained in combination with lapatinib. On the 
contrary, there are no significant differences in cell viability between cells treated with 
LY29004 alone or with LY29004 plus paclitaxel suggesting that LY29004 alone is the major 
determinant o f the observed decrease in cell viability.
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Figure 6.5 MTT test was used to test the efficacy o f paclitaxel in combination with the ERK 
1/2 inhibitor U0126, the PI3K inhibitor LY29004 and the drug lapatinib. MTT test was 
performed as described in Materials and Methods. Ovarian cancer cells were grown on 
96-well plates and treated for 24 hours at the following concentration o f  chemicals: paclitaxel 
5 pg/ml, U 0126 and LY29004 at 10 pM and lapatinib at 5 pM  and 10 pM. Values are mean 
+/- s.e.m. o f three independent experiments performed in triplicate
Next, we determined if the therapeutic potential o f LbL-paclitaxel nanocolloids could be 
further increased by the co-delivery o f paclitaxel and lapatinib. For this purpose, nanocolloids 
containing paclitaxel and lapatinib were prepared by LbL-technology. As shown in Figure. 
6.6, the particle size o f paclitaxel with one layer coating was 125 ± 50 nm, much smaller as 
compared with several micrometers o f original paclitaxel powder. We monitored the 
Layer-by-Layer coating process using the zeta potential analyzer (Figure 6.8 (a)), light 
scattering machine (Figure 6.8 (b)) and SEM (Figure 6.7). These results show that the 
consequrative coating process had been successful. After Layer-by-Layer coating with 
biocompatible and biodegradable layers of chitosan, alginic acid and lapatinib, the particle 
diameter was around 250 nm. Such architectural nanocapsules allowed dual delivery o f these 
two drugs.
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Figure 6.6 SEM images o f paclitaxel (a) and lapatinib (b) before treatment. Ultrasonication 
assisted coating o f first layer on paclitaxel: (c) Sonicator, (d) SEM image, (e) Light scattering 
result
Figure 6.7 SEM image o f Layer-by-Layer coating o f paclitaxel nanoparticles: (a) 
paclitaxel-(chitosan-alginic acid ) 3  and (b)paclitaxel-(chitosan-alginic acid)3 -laptinib-alginic 
acid
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Figure 6.8 Layer-by-Layer coating o f paclitaxel nanoparticles: (a) Zeta-potential and (b) 
Diameter as a function of coated layers
Results obtained by MTT test confirmed the enhanced cytotoxic activity o f this 
nanopreparation compared to paclitaxel free and LbL-paclitaxel (Figure 6.9).
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Figure 6.9 LbL-paclitaxel/lapatinib nanocolloids demonstrate significant cytotoxic 
activity in P-gp overexpressing ovarian cancer cells as determined by MTT test. Values are 
mean +/- s.e.m. o f three independent experiments performed in triplicate (p<0.05 *; p<0.01
**; p<0.001 ***).
6.4 Discussion
Ovarian cancer still remains one of the most fatal malignancies among women. 
Improving the efficacy of current therapeutics will have a great impact in the management o f 
the disease. Paclitaxel is widely used for the treatment of patients with ovarian cancer, but 
despite substantial clinical efficacy the optimal administration regimen remains elusive. 
Many questions remain concerning the way to administer the drug and the molecular 
mechanisms at the basis o f chemoresistance.
Among the proteins related to the chemoresistance process, the overexpression o f P-gp 
has profound implications in clinical practice. In fact, the presence of drug-efflux pumps that 
mediate the active efflux o f chemotherapeutics is one of the most extensively described
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mechanisms o f drug resistance, and strategies to modulate or block this process have been 
investigated actively in oncology [111]. In ovarian cancer, the expression o f  P-gp has been 
implicated in chemoresistance, correlated inversely with patient survival and associated with 
resistance to paclitaxel [102-114],
These observations set the stage for the development o f efficacious instruments to 
increase paclitaxel efficacy by limiting adverse side effects and increasing its cytotoxic action. 
In this regard, nanotechnology has been recognized as a fundamental tool in cancer research 
[115] and the potential o f nanocarriers to increase drug efficacy is well described [116-118].
6.5 Conclusions
Here, we describe a SLbL method to efficiently convert paclitaxel into drug NPs. It 
allows clinicians to combine many necessary factors for an efficient drug-delivery system: i) 
control of nanocolloid size within 100-300 nm, ii) high drug content o f approximately 70% 
wt, iii) shell biocompatibility and biodegradability, and iv) sustained controlled release. 
Overall, these characteristics, including the small size and the net negative charge, that can be 
advantageous for their penetration to and within tumors, make NPs attractive candidates for 
possible in vivo applications.
In addition, in this research we elaborated nanoformulation o f two drugs in one 
nanocapsule locating paclitaxel in the core and lapatinib on the shell periphery. The rationale 
for considering combination therapy is to overcome major problems associated with 
paclitaxel administration, such as the counteraction o f paclitaxel resistance and, in 
combination with dose-escalation, the potential reduction o f systemic toxicities. Moreover, 
with this strategy both drugs can be temporally co-localized in the tumor cells for optimal 
synergy, limiting possible differences in the pharmacokinetics and tumor accumulation o f the 
two different agents.
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Given the molecular complexity o f cancer, drug combinations are most likely to translate 
into a significant clinical benefit. To further increase the therapeutic potential o f nanocapsules, 
a research objective that remains to be explored regards the realization o f a target delivery 
system. Surface functionalization by targeting ligands or antibodies is an attractive 
opportunity to direct NPs toward cancer-specific cells or tumor-specific clones with 
substantially greater selectivity in tumor killing versus toxicity to normal host tissues. Several 
types of targeting ligands should be used for this purpose, including peptides and antibodies. 
These ligands enable NPs to bind specific receptors and to be internalized by endocytosis, 
enhancing the intracellular accumulation o f drugs. The feasibility of the LbL method makes 
easy the realization o f functionalized NPs by using polymers with free reactive groups for the 
outer layer o f LbL NPs. On the contrary, a relevant concern is the identification o f reliable 
ligands to impart a precise biological function to NPs. Significant research efforts have been 
made in a recent study from the National Cancer Institute Pilot Project for the acceleration o f 
translational research, where 75 possible tumor antigens were recognized [119]. Some of 
these tumor-associated antigens, including MUC1, CA 125, NY-ESO-1, and human 
epidermal GFR 2 (HER2)/neu are potential targets in ovarian cancer. In particular, due to its 
role in cellular transformation and tumorigenieity, MUC1 received great attention in those 
years. Recently, a monoclonal antibody anti-MUCl has been utilized alone or in combination 
with docetaxel (DTX) in preclinical models o f ovarian cancer, leading to a significant 
increase in survival. Furthermore, a MUC1 aptamer-guided nanoscale drug-deliverysystem 
was developed to enhance the paclitaxel delivery to MUC1- overexpressing MCF-7 cells in 
vitro [120-121],
To characterize the clinical potential o f nanocolloids loaded with paclitaxel and lapatinib, 
preclinical studies in animal tumor models are necessary, including a detailed evaluation of 
pharmacokinetics and pharmacodynamics and active intracellular intracellular delivery of
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LbL nanocolloids after intravenous or intraperitoneal administration. Extensive future 
research is warranted. Because many women experience recurrences during ovarian cancer 
therapy due to drug-resistance mechanisms, we postulate that our approach aiming at limiting 
this problem may serve the purpose o f improving the treatment o f  ovarian tumors.
CHAPTER 7
C O N C LU SIO N S A N D  FU TURE W O RK  
7.1 C onclusions
In this dissertation, the application o f  ultrasonication assisted Layer-by-Layer technology 
for the preparation of multifunctional nanoparticulated forms of poorly water-soluble 
anticancer drugs paclitaxel and lapatinib had been developed. Powerful ultra-sonication 
performed in the presence o f surface-active bubbling agents resulted in formation o f small 
drug nanoparticles o f desired size. To stabilize them, the Layer-by-Layer self-assembly o f 
multilayer films was built up with properties tailored by controlling the molecular makeup 
and arrangement with nanoscale precise film thickness. In this process, the nano-architectural 
approach designing layers o f different components, including ones serving as diffusion 
barrier and outermost layers charging, were realized.
Two different approaches with powerful ultrasonication, top-down approach (sonicating 
bulk drug crystals in polyelectrolyte solution) and bottom-up approach (sonicating drug in a 
water-miscible organic solvent followed by slowly water add-in) had been successfully 
applied for the preparation o f the nanoparticles o f paclitaxel and lapatinib, correspondingly. 
For the top-down approach, 200 nm diameter was a kind o f “magic” barrier for colloidal 
particles prepared. We suggested that it may be related to the nucleation size o f the solvent 
vapor microbubbles. This assumption allowed us to decrease paclitaxel colloid particles to 
120 nm diameter using agents enhancing bubbling formation (such as N H 4 H C O 3). However, 
a large obstacle o f these powerful ultrasonication methods were a necessity o f  long time (one
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hour) high power ultrasonication resulted in TiCE nanoparticle detachment from titanium 
electrode and contamination o f the sample. Such formed paclitaxel nanoparticles were LbL 
coated with 10-20 nm polycation/polyanion shell to provide aqeous colloidal stability and 
slower particle dissolution. Mice injection was possible but demanded TiCE purification.
With the bottom-up approach (based on desolvation of the drug diluted in alcohole), less 
powerful sonication was used, and prepared particle sizes of 140-150 nm were obtained both 
for lapatinib and paclitaxel. Less sonification time (ca 15 minutes) allowed avoiding TiCE 
contamination. Regular sonicatation combined with our LbL approach and traditional 
emulsification process with addition o f biodegradable surfactants to anchor polyelectrolytes 
on the surface o f the formed drug nanoparticles had been applied to avoid the Ti pollution 
created by powerful ultrasonication. The bottom-up approach using polymeric excipients 
combined with non-ionic and anionic surfactants along with regular sonication allows 
preparing uniform 140-150 nm colloid cores o f lapatinib. The amphiphiles attach to the 
hydrophobic nanoparticles and serves as anchors for LbL shell. In contrast to untangled 
amphiphiles, LbL polyelectrolyte shells do not detach easily from the surface and retain 
integrity upon dilution in another media. The inner LbL layers and surfactants minimize the 
surface free energy, thereby preventing crystal form changes and nanoparticles coalescence, 
while the outermost layers enhance colloidal stability.
To overcome difficulties with drug nanoformulation colloidal stability in high molarity 
PBS buffer, we developed LbL shells with PEGylation for lapatinib. For these shells, we 
used block-copolymer o f cationic polylysine with PEG. The best stable in PBS buffer 
nanoformulations o f lapatinib have shells consisting o f a block copolymer o f poly-L-lysine 
(PLL) and PEG of different length (PLB) as a positive component of the shell and heparin as 
a negative component. Better colloidal stability o f  lapatinib dispersions in PBS was obtained 
while using PLB copolymer at every bilayer with the shell architecture o f  (PLB/heparin) 3 5 .
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In the proposed paclitaxel and lapatinib formulation, we obtained 150-200 nm with high 
drug content o f 80-90 % due to very thin capsule walls (of ca 10 nm). The drug release time 
from the LbL capsules was found to be between 10 and 20 hours depending on the shell 
thickness. Washless LbL assembly had been used: 1) addition o f polycation in the amount 
that is enough to reverse surface charge o f the dispersion to a high positive (+30 mV) value; 
2) addition o f polyanion in the amount that is enough to reverse surface charge o f the 
dispersion to a high negative (-30 mV) value. No intermediate washing o f nanoparticles was 
done until the shell was complete.
We elaborated nanoformulation o f two drugs in one nanocapsule locating paclitaxel in the 
core and lapatinib on the shell periphery. With this formulation o f combining in one 
nanoparticle dual drug we reached the drugs efficiency synergy. In a multidrug-resistant 
(MDR) ovarian cancer cell line, OVCAR-3, lapatinib/paclitaxel nanocolloids mediated an 
enhanced cell growth inhibition in comparison with the paclitaxel-only treatment.
7.2 Future Work
Upon completion of this research, the following ideas for future work were suggested. 
The first idea is the application o f the bubbling agent for the bottom-up approach with regular 
ultrasoincaton to get even smaller particle sizes without the pollution o f powerful 
ultrasonication. The second idea is trying different encapsulation methods for the preparation 
o f dual drugs.
To further increase the therapeutic potential o f nanocapsules, a target delivery system for 
anticancer drugs paclitaxel and lapatinib remains to be explored. Surface functionalization by 
targeting ligands or antibodies is an attractive opportunity' to direct nanoparticles toward 
cancer-specific cells or tumor-specific clones with substantially greater selectivity in tumor 
killing versus toxicity to normal host tissues. Several types o f targeting ligands should be
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used for this purpose, including peptides and antibodies. The feasibility o f the LbL method 
makes easy the realization o f functionalized nanoparticles by using polymers with free 
reactive groups for the outer layer o f LbL shell. Significant research efforts have been made 
in a recent study from the National Cancer Institute Pilot Project for the acceleration o f 
translational research, where 75 possible tumor antigens were recognized [119-121],
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